\n\n\n\n \nMichael R. Grunwald\
, MD \nChief\, Leukemia Division \nDirector\, Transplan
tation and Cellular Therapy Program \nAssociate Professor \nLevi
ne Cancer Institute\, Atrium Health \nCharlotte\, NC \n | \n\n\n Ryan Jacobs\, MD \nPrincipal Investi
gator of CLL Clinical Trials \nDepartment of Hematology\, Lymphoma Di
vision \nAssistant Professor of Medicine \nLevine Cancer Institu
te\, Atrium Health \nCharlotte\, NC \n | \n
\n\n\n\nPROGRAM OVERVIEW
\nThis activity
will explore the management of patients with acute myeloid leukemia (AML)
and chronic lymphocytic leukemia (CLL)\, including the impact of molecula
r markers\, genetic data\, and patient characteristics on treatment select
ion\; and potential adverse events of AML and CLL treatments.
\nTARGET AUDIENCE
\nThis multi-modular educational init
iative is intended for US-based hematologists\, medical oncologists\, and
other healthcare providers involved in the management of patients with CLL
and/or AML.
\nLEARNING OBJECTIVES
\nUpon c
ompletion of the program\, attendees should be able to:
\n\n- Sum
marize the relevance of molecular markers and genetic data relevant to sel
ection of therapy in CLL or AML
\n- Review relevant treatment best p
ractices in both newly diagnosed and relapsed/refractory AML in considerat
ion of disease- and patient-specific factors to inform shared decision-mak
ing
\n- Evaluate potential adverse events associated with CLL and AM
L therapies to implement appropriate monitoring and counseling
\n
\nACCREDITATION STATEMENT
\nMed Learning Group
is accredited by the Accreditation Council for Continuing Medical Educati
on to provide continuing medical education for physicians. This CME activi
ty was planned and produced in accordance with the ACCME Essentials.
\n
CREDIT DESIGNATION STATEMENT
\nMed Learning Gr
oup designates this online activity for a maximum of 1.0 AMA PRA Category
1 CreditTM. Physicians should claim only the credit commensurat
e with the extent of their participation in the online activity.
\n
NURSING CREDIT INFORMATION
\nPurpose: This program
would be beneficial for nurses involved in the care of patients with CLL
and/or AML.
\nCNE Credits: 1.0 ANCC Contact Hour.
p>\n
CNE ACCREDITATION STATEMENT
\nUltimate Med
ical Academy/Complete Conference Management (CCM) is accredited as a provi
der of nursing continuing professional education development by the Americ
an Nurses Credentialing Center’s Commission on Accreditation.
\nAward
ed 1.0 contact hour of continuing nursing education of RNs and APNs.
\n
DISCLOSURE POLICY STATEMENT
\nIn accordance wi
th the Accreditation Council for Continuing Medical Education (ACCME) Stan
dards for Commercial Support\, educational programs sponsored by Med Learn
ing Group must demonstrate balance\, independence\, objectivity\, and scie
ntific rigor. All faculty\, authors\, editors\, staff\, and planning commi
ttee members participating in an MLG-sponsored activity are required to di
sclose any relevant financial interest or other relationship with the manu
facturer(s) of any commercial product(s) and/or provider(s) of commercial
services that are discussed in an educational activity.
\nD
ISCLOSURE OF CONFLICTS OF INTEREST
\nMichael R
. Grunwald\, MD\, receives consulting fees from AbbVie\, Agi
os/Servier\, Amgen\, Astellas Pharma\, Blueprint Medicines\, Bristol Myers
Squibb\, Cardinal Health\, CTI Biopharma\, Daiichi Sankyo\, Gamida Cell\,
Gilead Sciences\, Incyte Corporation\, Invitae\, Karius\, Novartis\, Ono
Pharmaceutical\, Pfizer\, Premier\, Sierra Oncology\, and Stemline Therape
utics\; he receives research funding (institution) from Janssen and has st
ock ownership in Medtronic.
\nRyan Jacobs\, MD<
/em>\, receives consulting fees from Adaptive\, Genentech\, MorphoSys\, Se
cura Bio\, and TG Therapeutics\; he has served on the speaker’s bureau for
AbbVie\, AstraZeneca\, Janssen\, Pharmacyclics\, Secura Bio\, and TG Ther
apeutics. He has also received research funding from LOXO\, MEI Pharma\, P
harmacyclics\, and Teneobio.
\nCME Content Review<
/h4>\n
The content of this activity was independently peer reviewed.
\nThe reviewer of this activity has nothing to disclose.
\nCNE Content Review
\nThe content of this activity was pe
er reviewed by a nurse reviewer.
\nDouglas Cox\, MSN\, MHA\, RN
\nUltimate Medical Academy/CCM – Lead Nurse Planner
\nThe reviewer of
this activity has nothing to disclose.
\nStaff Planners an
d Managers
\nThe staff\, planners\, and managers reported
the following financial relationships or relationships to products or devi
ces they or their spouse/life partner have with commercial interests relat
ed to the content of this CME/CE activity:
\nMatthew Frese\, MBA\, G
eneral Manager of Med Learning Group\, has nothing to disclose.
\nCh
ristina Gallo\, SVP\, Educational Development for Med Learning Group\, has
nothing to disclose.
\nAngela L. Davis\, PhD\, Director\, Medical &
Scientific Services for Med Learning Group has nothing to disclose.
\n
Lauren Welch\, MA\, VP\, Accreditation and Outcomes for Med Learning Gr
oup\, has nothing to disclose.
\nJessica McMullen\, MPH\, Program Ma
nager for Med Learning Group\, has nothing to disclose.
\nRussie All
en\, Accreditation and Outcomes Manager for Med Learning Group\, has nothi
ng to disclose.
\nDouglas Cox\, MSN\, MHA\, RN\, UMA/CCM – LNP\, has
nothing to disclose.
\nDISCLOSURE OF UNLABELED USE
\nMed Learning Group requires that faculty participating in any C
ME activity disclose to the audience when discussing any unlabeled or inve
stigational use of any commercial product or device not yet approved for u
se in the United States. During this lecture\, the faculty may mention the
use of medications for both FDA-approved and non-approved indications.
\nMETHOD OF PARTICIPATION
\nThere are no fees
for participating and receiving CME credit for this online activity. To r
eceive CME/CNE credit participants must:
\n\n- Read the CME/CNE i
nformation and faculty disclosures.
\n- Participate in the online ac
tivity.
\n- Complete the online post-test and evaluation.
\n
\nYou will receive your certificate as a downloadable file.
\n<
strong>DISCLAIMER
\nMed Learning Group makes every effort
to develop CME activities that are science based. This activity is designe
d for educational purposes. Participants have a responsibility to use this
information to enhance their professional development in an effort to imp
rove patient outcomes. Conclusions drawn by the participants should be der
ived from careful consideration of all available scientific information. T
he participant should use his/her clinical judgment\, knowledge\, experien
ce\, and diagnostic decision making before applying any information\, whet
her provided here or by others\, for any professional use.
\nFor CME
questions\, please contact Med Learning Group at info@medlearninggroup.com
\nC
ontact this CME provider at Med Learning Group for privacy and confidentia
lity policy statement information at http://medlearninggroup.com/privacy-polic
y/
\nAMERICANS WITH DISABILITIES ACT
\n
Staff will be glad to assist you with any special needs. Please contact Me
d Learning Group prior to participating at info@medlearninggroup.com
\n\nCopyright ©2022 Med Learning Group. All
rights reserved. These materials may be used for personal use only. Any r
ebroadcast\, distribution\, or reuse of this presentation or any part of i
t in any form for other than personal use without the express written perm
ission of Med Learning Group is prohibited.
\nView Activity AML and CLL Med Games Toolkit Poster Portal
\nExtra Resources
\nVideo Case Study 1 Video Case Study 2
\n<
p> \n\n\n \n \n
END:VEVENT
BEGIN:VEVENT
UID:ai1ec-205744@catalyst-hm.com
DTSTAMP:20240328T180159Z
CATEGORIES;LANGUAGE=en-US:Online Programs
CONTACT:
DESCRIPTION:Approaches to Improving Care in Chronic Lymphocytic Leukemia in
the Veteran’s Affairs System: Insights from the Experts\n\nView Activity
\nPROGRAM CHAIR & FACULTY PRESENTER\nRyan Jacobs\, MD\nPrincipal Investiga
tor of CLL Clinical Trials\nAssistant Professor\, Atrium Health\nDepartmen
t of Hematology\, Lymphoma Section\nLevine Cancer Institute\nCharlotte\, N
C\nPROGRAM OVERVIEW\nThis activity will explore the management of patients
with of treatment-naïve and relapsed/refractory chronic lymphocytic leuke
mia (CLL). This program will address approaches to individualize selection
of therapy and the role of minimal residual disease (MRD) in monitoring t
reatment effectiveness. A summary of approaches to TRAE recognition and mi
tigation will also be addressed.\nTARGET AUDIENCE\nThis educational activi
ty is intended for hematologists\, community oncologists and clinicians in
volved in the assessment\, monitoring\, and treatment of CLL in the Depart
ment of Veterans Affairs.\nLEARNING OBJECTIVES\nUpon completion of the pro
gram\, attendees should be able to:\n\nAssess how genetic and molecular ma
rkers aid in determining treatment strategies for patients with CLL\nEvalu
ate the role of MRD in monitoring the effectiveness of treatment approache
s for CLL and its clinical implications\nIndividualize selection of therap
ies for the treatment of treatment-naïve and relapsed/refractory (R/R) CLL
based on disease‐ and patient‐specific factors to communicate these treat
ment plans using shared decision-making strategies\nRecognize adverse even
ts associated with CLL treatment to appropriately prevent and/or manage th
ese potential effects\n\nACCREDITATION STATEMENT\nMed Learning Group is ac
credited by the Accreditation Council for Continuing Medical Education to
provide continuing medical education for physicians.\nThis CME activity wa
s planned and produced in accordance with the ACCME Essentials.\nCREDIT DE
SIGNATION STATEMENT\nMed Learning Group designates this enduring activity
for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim
only the credit commensurate with the extent of their participation in the
online activity.\nNURSING CREDIT INFORMATION\nPurpose: This program would
be beneficial for nurses involved in the care of patients with chronic ly
mphocytic leukemia.\nCNE Credits: 1.0 ANCC Contact Hour.\nCNE ACCREDITATIO
N STATEMENT\nUltimate Medical Academy/Complete Conference Management (CCM)
is accredited as a provider of nursing continuing professional education
development by the American Nurses Credentialing Center’s Commission on Ac
creditation.\nAwarded 1.0 contact hour of continuing nursing education of
RNs and APNs.\nDISCLOSURE POLICY STATEMENT\nIn accordance with the Accredi
tation Council for Continuing Medical Education (ACCME) Standards for Comm
ercial Support\, educational programs sponsored by Med Learning Group must
demonstrate balance\, independence\, objectivity\, and scientific rigor.
All faculty\, authors\, editors\, staff\, and planning committee members p
articipating in an MLG-sponsored activity are required to disclose any rel
evant financial interest or other relationship with the manufacturer(s) of
any commercial product(s) and/or provider(s) of commercial services that
are discussed in an educational activity.\nDISCLOSURE OF CONFLICTS OF INTE
REST\nDr. Jacobs has received consulting fees from Secura Bio\, Genentech\
, Adaptive\, TG Therapeutics\, and MorphoSys\; he has served on the speake
r’s bureau for Pharmacyclics\, Janssen\, AbbVie\, TG Therapeutics\, Secura
Bio\, and AstraZeneca. He has also received research funding from Pharmac
yclics\, Teneobio\, MEI Pharma\, and LOXO.\nCME Content Review\nThe conten
t of this activity was independently peer reviewed.\nThe reviewer of this
activity has nothing to disclose.\nCNE Content Review\nThe content of this
activity was peer reviewed by a nurse reviewer.\nDouglas Cox\, MSN\, MHA\
, RN\nUltimate Medical Academy/CCM – Lead Nurse Planner\nThe reviewer of t
his activity has nothing to disclose.\nStaff Planners and Managers\nThe st
aff\, planners\, and managers reported the following financial relationshi
ps or relationships to products or devices they or their spouse/life partn
er have with commercial interests related to the content of this CME/CE ac
tivity:\n\nMatthew Frese\, MBA\, General Manager of Med Learning Group\, h
as nothing to disclose.\nChristina Gallo\, SVP\, Educational Development f
or Med Learning Group\, has nothing to disclose.\nJames Seternus\, DO\, Me
dical & Scientific Services for Med Learning Group has nothing to disclose
.\nLauren Welch\, MA\, VP\, Accreditation and Outcomes for Med Learning Gr
oup\, has nothing to disclose.\nJessica McMullen\, MPH\, Program Manager f
or Med Learning Group\, has nothing to disclose.\nRussie Allen\, Accredita
tion and Outcomes Manager for Med Learning Group\, has nothing to disclose
.\nDouglas Cox\, MSN\, MHA\, RN\, UMA/CCM – LNP\, has nothing to disclose.
\n\nDISCLOSURE OF UNLABELED USE\nMed Learning Group requires that faculty
participating in any CME activity disclose to the audience when discussing
any unlabeled or investigational use of any commercial product or device
not yet approved for use in the United States.\nDuring this lecture\, the
faculty may mention the use of medications for both FDA-approved and non-a
pproved indications.\nMETHOD OF PARTICIPATION\nThere are no fees for parti
cipating and receiving CME credit for this enduring activity. To receive C
ME/CNE credit participants must:\n\nRead the CME/CNE information and facul
ty disclosures.\nParticipate in the online activity.\nComplete the online
post-test and evaluation.\n\nYou will receive your certificate as a downlo
adable file.\nDISCLAIMER\nMed Learning Group makes every effort to develop
CME activities that are science based. This activity is designed for educ
ational purposes. Participants have a responsibility to use this informati
on to enhance their professional development in an effort to improve patie
nt outcomes. Conclusions drawn by the participants should be derived from
careful consideration of all available scientific information. The partici
pant should use his/her clinical judgment\, knowledge\, experience\, and d
iagnostic decision making before applying any information\, whether provid
ed here or by others\, for any professional use.\nFor CME questions\, plea
se contact Med Learning Group at info@medlearninggroup.com\nContact this C
ME provider at Med Learning Group for privacy and confidentiality policy s
tatement information at http://medlearninggroup.com/privacy‐policy/\nAMERI
CANS WITH DISABILITIES ACT\nStaff will be glad to assist you with any spec
ial needs. Please contact Med Learning Group prior to participating at inf
o@medlearninggroup.com\nRELEASE DATE: July 07\, 2022\nEXPIRATION DATE: Jul
y 07\, 2023\n\nCopyright © 2022 Med Learning Group. All rights reserved. T
hese materials may be used for personal use only. Any rebroadcast\, distri
bution\, or reuse of this presentation or any part of it in any form for o
ther than personal use without the express written permission of Med Learn
ing Group is prohibited.\n \nView Activity\n
DTSTART;TZID=America/New_York:20220706T180300
DTEND;TZID=America/New_York:20230706T190300
SEQUENCE:0
SUMMARY:Approaches to Improving Care in Chronic Lymphocytic Leukemia in the
Veteran’s Affairs System: Insights from the Experts
URL:https://catalyst-hm.com/event/approaches-to-improving-care-in-chronic-l
ymphocytic-leukemia-in-the-veterans-affairs-system-insights-from-the-exper
ts/
X-COST-TYPE:free
X-WP-IMAGES-URL:thumbnail\;https://catalyst-hm.com/wp-content/uploads/2022/
07/h175n.jpg\;1220\;187\,medium\;https://catalyst-hm.com/wp-content/upload
s/2022/07/h175n.jpg\;1220\;187\,large\;https://catalyst-hm.com/wp-content/
uploads/2022/07/h175n.jpg\;1220\;187\,full\;https://catalyst-hm.com/wp-con
tent/uploads/2022/07/h175n.jpg\;1220\;187
X-ALT-DESC;FMTTYPE=text/html:\\n\\n
\\n\\n\\n\n
\n
\n
\n
Approaches to Improving Care in Chronic Lymphocytic Leukemia in the Vet
eran’s Affairs System: Insights from the Experts
\n
\n
View Activity
\n<
h3>
PROGRAM CHAIR & FACULTY PRESENTER\n
Rya
n Jacobs\, MD
\nPrincipal Investigator of CLL Clinical Trial
s
\nAssistant Professor\, Atrium Health
\nDepartment of Hematolo
gy\, Lymphoma Section
\nLevine Cancer Institute
\nCharlotte\, NC
\n
PROGRAM OVERVIEW
\n
This activity will ex
plore the management of patients with of treatment-naïve and relapsed/refr
actory chronic lymphocytic leukemia (CLL). This program will address appro
aches to individualize selection of therapy and the role of minimal residu
al disease (MRD) in monitoring treatment effectiveness. A summary of appro
aches to TRAE recognition and mitigation will also be addressed.
\n
TARGET AUDIENCE
\n
This educational activity is int
ended for hematologists\, community oncologists and clinicians involved in
the assessment\, monitoring\, and treatment of CLL in the Department of V
eterans Affairs.
\n
LEARNING OBJECTIVES
\n
Up
on completion of the program\, attendees should be able to:
\n
\n- Assess how genetic and molecular markers aid in determining treatment str
ategies for patients with CLL
\n- Evaluate the role of MRD in monito
ring the effectiveness of treatment approaches for CLL and its clinical im
plications
\n- Individualize selection of therapies for the treatmen
t of treatment-naïve and relapsed/refractory (R/R) CLL based on disease‐ a
nd patient‐specific factors to communicate these treatment plans using sha
red decision-making strategies
\n- Recognize adverse events associat
ed with CLL treatment to appropriately prevent and/or manage these potenti
al effects
\n
\n
ACCREDITATION STATEMENT
\n
Med Learning Group is accredited by the Accreditation Council for Con
tinuing Medical Education to provide continuing medical education for phys
icians.
\n
This CME activity was planned and produced in accordance w
ith the ACCME Essentials.
\n
CREDIT DESIGNATION STATEMENT
\n
Med Learning Group designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physician
s should claim only the credit commensurate with the extent of their parti
cipation in the online activity.
\n
NURSING CREDIT INFORMATI
ON
\n
Purpose: This program would be benef
icial for nurses involved in the care of patients with chronic lymphocytic
leukemia.
\nCNE Credits: 1.0 ANCC Contact Hour.
\n
CNE ACCREDITATION STATEMENT
\n
Ultimate Medic
al Academy/Complete Conference Management (CCM) is accredited as a provide
r of nursing continuing professional education development by the American
Nurses Credentialing Center’s Commission on Accreditation.
\n
Awarde
d 1.0 contact hour of continuing nursing education of RNs and APNs.
\n<
h3>
DISCLOSURE POLICY STATEMENT\n
In accordance wit
h the Accreditation Council for Continuing Medical Education (ACCME) Stand
ards for Commercial Support\, educational programs sponsored by Med Learni
ng Group must demonstrate balance\, independence\, objectivity\, and scien
tific rigor. All faculty\, authors\, editors\, staff\, and planning commit
tee members participating in an MLG-sponsored activity are required to dis
close any relevant financial interest or other relationship with the manuf
acturer(s) of any commercial product(s) and/or provider(s) of commercial s
ervices that are discussed in an educational activity.
\n
DI
SCLOSURE OF CONFLICTS OF INTEREST
\n
Dr. Jacobs
has received consulting fees from Secura Bio\, Genentech\,
Adaptive\, TG Therapeutics\, and MorphoSys\; he has served on the speaker’
s bureau for Pharmacyclics\, Janssen\, AbbVie\, TG Therapeutics\, Secura B
io\, and AstraZeneca. He has also received research funding from Pharmacyc
lics\, Teneobio\, MEI Pharma\, and LOXO.
\n
CME Content Revi
ew
\n
The content of this activity was independently peer r
eviewed.
\nThe reviewer of this activity has nothing to disclose.
\n
CNE Content Review
\n
The content of this act
ivity was peer reviewed by a nurse reviewer.
\n
Douglas Cox\, MSN\, M
HA\, RN
\nUltimate Medical Academy/CCM – Lead Nurse Planner
\n
T
he reviewer of this activity has nothing to disclose.
\n
Sta
ff Planners and Managers
\n
The staff\, planners\, and mana
gers reported the following financial relationships or relationships to pr
oducts or devices they or their spouse/life partner have with commercial i
nterests related to the content of this CME/CE activity:
\n
\n- Ma
tthew Frese\, MBA\, General Manager of Med Learning Group\, has nothing to
disclose.
\n- Christina Gallo\, SVP\, Educational Development for M
ed Learning Group\, has nothing to disclose.
\n- James Seternus\, DO
\, Medical & Scientific Services for Med Learning Group has nothing to dis
close.
\n- Lauren Welch\, MA\, VP\, Accreditation and Outcomes for M
ed Learning Group\, has nothing to disclose.
\n- Jessica McMullen\,
MPH\, Program Manager for Med Learning Group\, has nothing to disclose.\n
- Russie Allen\, Accreditation and Outcomes Manager for Med Learning
Group\, has nothing to disclose.
\n- Douglas Cox\, MSN\, MHA\, RN\,
UMA/CCM – LNP\, has nothing to disclose.
\n
\n
DISCLOS
URE OF UNLABELED USE
\n
Med Learning Group requires that fa
culty participating in any CME activity disclose to the audience when disc
ussing any unlabeled or investigational use of any commercial product or d
evice not yet approved for use in the United States.
\n
During this l
ecture\, the faculty may mention the use of medications for both FDA-appro
ved and non-approved indications.
\n
METHOD OF PARTICIPATION
\n
There are no fees for participating and receiving CME c
redit for this enduring activity. To receive CME/CNE credit participants m
ust:
\n
\n- Read the CME/CNE information and faculty disclosures.<
/li>\n
- Participate in the online activity.
\n- Complete the onlin
e post-test and evaluation.
\n
\n
You will receive your certific
ate as a downloadable file.
\n
DISCLAIMER
\n
Med Learning Group makes every effort to develop CME activities that are s
cience based. This activity is designed for educational purposes. Particip
ants have a responsibility to use this information to enhance their profes
sional development in an effort to improve patient outcomes. Conclusions d
rawn by the participants should be derived from careful consideration of a
ll available scientific information. The participant should use his/her cl
inical judgment\, knowledge\, experience\, and diagnostic decision making
before applying any information\, whether provided here or by others\, for
any professional use.
\n
For CME questions\, please contact Med Lear
ning Group at i
nfo@medlearninggroup.com
\n
Contact this CME provider at Med Lear
ning Group for privacy and confidentiality policy statement information at
htt
p://medlearninggroup.com/privacy‐policy/
\n
AMERICANS WI
TH DISABILITIES ACT
\n
Staff will be glad to assist you wit
h any special needs. Please contact Med Learning Group prior to participat
ing at info@medlearninggroup.com
\n
RELEASE DATE: Ju
ly 07\, 2022
\n
EXPIRATION DATE: July 07\, 2023
\n
\n
Copyright © 2022 Med Learn
ing Group. All rights reserved. These materials may be used for personal u
se only. Any rebroadcast\, distribution\, or reuse of this presentation or
any part of it in any form for other than personal use without the expres
s written permission of Med Learning Group is prohibited.
\n
\n<
p style='text-align: center\;'>
View Activity\n
\n
\n\n
\n
\n
END:VEVENT
BEGIN:VEVENT
UID:ai1ec-205749@catalyst-hm.com
DTSTAMP:20240328T180159Z
CATEGORIES;LANGUAGE=en-US:Online Programs
CONTACT:
DESCRIPTION:Optimizing the Care of Patients with Relapsed/Refractory MCL an
d CLL/SLL in the Veteran’s Administration System: Evaluating Evidence-Base
d Management\n\nView Activity\nPROGRAM CHAIR & FACULTY PRESENTER\nRyan Jac
obs\, MD\nDepartment of Hematology\, Lymphoma Division\nAssistant Professo
r of Medicine\nLevine Cancer Institute/Atrium Health\nCharlotte\, NC\nPROG
RAM OVERVIEW\nThis activity will explore emerging treatment options and no
vel management strategies of patients with relapsed/refractory MCL or CLL/
SLL.\nTARGET AUDIENCE\nThis activity is designed to meet the educational n
eeds of hematologists\, oncologists\, and other community-based healthcare
practitioners who care for patients with MCL and CLL/SLL within the Veter
ans Affairs health system.\nLEARNING OBJECTIVES\nUpon completion of the pr
ogram\, attendees should be able to:\n\nExamine needs for immunophenotypin
g and evaluation of genetic data to inform CLL/SLL and MCL management in t
he first-line setting and beyond\nConsider efficacy and safety data with e
merging therapies for CLL/SLL and MCL management in consideration of curre
nt guidelines\nDiscuss unique mechanistic features of specific therapies\,
as well as adverse event profiles and the rationale for use in relapsed/r
efractory patients\n\nACCREDITATION STATEMENT\nMed Learning Group is accre
dited by the Accreditation Council for Continuing Medical Education to pro
vide continuing medical education for physicians. This CME activity was pl
anned and produced in accordance with the ACCME Essentials.\nCREDIT DESIGN
ATION STATEMENT\nMed Learning Group designates this enduring activity for
a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only
the credit commensurate with the extent of their participation in the onl
ine activity.\nNURSING CREDIT INFORMATION\nPurpose: This program would be
beneficial for nurses involved in the care of patients with relapsed/refra
ctory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/sm
all lymphocytic leukemia (SLL).\nCNE Credits: 1.0 ANCC Contact Hour.\nCNE
ACCREDITATION STATEMENT\nUltimate Medical Academy/Complete Conference Mana
gement (CCM) is accredited as a provider of nursing continuing professiona
l education development by the American Nurses Credentialing Center’s Comm
ission on Accreditation.\nAwarded 1.0 contact hour of continuing nursing e
ducation of RNs and APNs.\nDISCLOSURE POLICY STATEMENT\nIn accordance with
the Accreditation Council for Continuing Medical Education (ACCME) Standa
rds for Commercial Support\, educational programs sponsored by Med Learnin
g Group must demonstrate balance\, independence\, objectivity\, and scient
ific rigor. All faculty\, authors\, editors\, staff\, and planning committ
ee members participating in an MLG-sponsored activity are required to disc
lose any relevant financial interest or other relationship with the manufa
cturer(s) of any commercial product(s) and/or provider(s) of commercial se
rvices that are discussed in an educational activity.\nDISCLOSURE OF CONFL
ICTS OF INTEREST\nRyan Jacobs\, MD\, receives consulting fees from Adaptiv
e\, Genentech\, MorphoSys\, Secura Bio\, and TG Therapeutics\; he has serv
ed on the speaker’s bureau for AbbVie\, AstraZeneca\, Janssen\, Pharmacycl
ics\, Secura Bio\, and TG Therapeutics. He has also received research fund
ing from LOXO\, MEI Pharma\, Pharmacyclics\, and Teneobio.\nCME Content Re
view\nThe content of this activity was independently peer reviewed.\nThe r
eviewer of this activity has nothing to disclose.\nCNE Content Review\nThe
content of this activity was peer reviewed by a nurse reviewer.\nDouglas
Cox\, MSN\, MHA\, RN\nUltimate Medical Academy/CCM – Lead Nurse Planner\nT
he reviewer of this activity has nothing to disclose.\nStaff Planners and
Managers\nThe staff\, planners\, and managers reported the following finan
cial relationships or relationships to products or devices they or their s
pouse/life partner have with commercial interests related to the content o
f this CME/CE activity:\n\nMatthew Frese\, MBA\, General Manager of Med Le
arning Group\, has nothing to disclose.\nChristina Gallo\, SVP\, Education
al Development for Med Learning Group\, has nothing to disclose.\nJames Se
ternus\, DO\, Medical & Scientific Services for Med Learning Group has not
hing to disclose.\nLauren Welch\, MA\, VP\, Accreditation and Outcomes for
Med Learning Group\, has nothing to disclose.\nJessica McMullen\, MPH\, P
rogram Manager for Med Learning Group\, has nothing to disclose.\nRussie A
llen\, Accreditation and Outcomes Manager for Med Learning Group\, has not
hing to disclose.\nDouglas Cox\, MSN\, MHA\, RN\, UMA/CCM – LNP\, has noth
ing to disclose.\n\nDISCLOSURE OF UNLABELED USE\nMed Learning Group requir
es that faculty participating in any CME activity disclose to the audience
when discussing any unlabeled or investigational use of any commercial pr
oduct or device not yet approved for use in the United States. During this
lecture\, the faculty may mention the use of medications for both FDA-app
roved and non-approved indications.\nMETHOD OF PARTICIPATION\nThere are no
fees for participating and receiving CME credit for this enduring activit
y. To receive CME/CNE credit participants must:\n\nRead the CME/CNE inform
ation and faculty disclosures.\nParticipate in the online activity.\nCompl
ete the online post-test and evaluation.\n\nYou will receive your certific
ate as a downloadable file.\nDISCLAIMER\nMed Learning Group makes every ef
fort to develop CME activities that are science based. This activity is de
signed for educational purposes. Participants have a responsibility to use
this information to enhance their professional development in an effort t
o improve patient outcomes. Conclusions drawn by the participants should b
e derived from careful consideration of all available scientific informati
on. The participant should use his/her clinical judgment\, knowledge\, exp
erience\, and diagnostic decision making before applying any information\,
whether provided here or by others\, for any professional use.\nFor CME q
uestions\, please contact Med Learning Group at info@medlearninggroup.com
\nContact this CME provider at Med Learning Group for privacy and confiden
tiality policy statement information at http://medlearninggroup.com/privac
y‐policy/\nAMERICANS WITH DISABILITIES ACT\nStaff will be glad to assist y
ou with any special needs. Please contact Med Learning Group prior to part
icipating at info@medlearninggroup.com\nRELEASE DATE: August 03\, 2022\nEX
PIRATION DATE: August 03\, 2023\n\nCopyright © 2022 Med Learning Group. Al
l rights reserved. These materials may be used for personal use only. Any
rebroadcast\, distribution\, or reuse of this presentation or any part of
it in any form for other than personal use without the express written per
mission of Med Learning Group is prohibited.\n \nView Activity\n
DTSTART;TZID=America/New_York:20220803T173400
DTEND;TZID=America/New_York:20230803T183400
SEQUENCE:0
SUMMARY:Optimizing the Care of Patients with Relapsed/Refractory MCL and CL
L/SLL in the Veteran’s Administration System: Evaluating Evidence-Based Ma
nagement
URL:https://catalyst-hm.com/event/optimizing-the-care-of-patients-with-rela
psed-refractory-mcl-and-cll-sll-in-the-veterans-administration-system-eval
uating-evidence-based-managementapproaches-to-improving-care-in-chronic-ly
m/
X-COST-TYPE:free
X-WP-IMAGES-URL:thumbnail\;https://catalyst-hm.com/wp-content/uploads/2022/
08/f193.jpg\;1220\;187\,medium\;https://catalyst-hm.com/wp-content/uploads
/2022/08/f193.jpg\;1220\;187\,large\;https://catalyst-hm.com/wp-content/up
loads/2022/08/f193.jpg\;1220\;187\,full\;https://catalyst-hm.com/wp-conten
t/uploads/2022/08/f193.jpg\;1220\;187
X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\n\\n\\n\n
\n
\n
\n
O
ptimizing the Care of Patients with Relapsed/Refractory MCL and CLL/SLL in
the Veteran’s Administration System: Evaluating Evidence-Based Management
\n
\n
View Activity
\n
PROGRAM CHAIR & FACULTY PRESENTER
\n
Ryan Jacobs\, MD
\nDepartment of Hema
tology\, Lymphoma Division
\nAssistant Professor of Medicine
\nL
evine Cancer Institute/Atrium Health
\nCharlotte\, NC
\n
PROGRAM OVERVIEW
\n
This activity will explore emerging t
reatment options and novel management strategies of patients with relapsed
/refractory MCL or CLL/SLL.
\n
TARGET AUDIENCE
\n
This activity is designed to meet the educational needs of hematologi
sts\, oncologists\, and other community-based healthcare practitioners who
care for patients with MCL and CLL/SLL within the Veterans Affairs health
system.
\n
LEARNING OBJECTIVES
\n
Upon compl
etion of the program\, attendees should be able to:
\n
\n- Examine
needs for immunophenotyping and evaluation of genetic data to inform CLL/
SLL and MCL management in the first-line setting and beyond
\n- Cons
ider efficacy and safety data with emerging therapies for CLL/SLL and MCL
management in consideration of current guidelines
\n- Discuss unique
mechanistic features of specific therapies\, as well as adverse event pro
files and the rationale for use in relapsed/refractory patients
\n
\n
ACCREDITATION STATEMENT
\n
Med Learning Grou
p is accredited by the Accreditation Council for Continuing Medical Educat
ion to provide continuing medical education for physicians. This CME activ
ity was planned and produced in accordance with the ACCME Essentials.
\n
CREDIT DESIGNATION STATEMENT
\n
Med Learning
Group designates this enduring activity for a maximum of 1.0 AMA PRA C
ategory 1 CreditTM. Physicians should claim only the credi
t commensurate with the extent of their participation in the online activi
ty.
\n
NURSING CREDIT INFORMATION
\n
Purpose: This program would be beneficial for nurses involved in
the care of patients with relapsed/refractory mantle cell lymphoma (MCL) a
nd chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).
\nCNE Credits: 1.0 ANCC Contact Hour.
\n
CNE ACCREDITATION STATEMENT
\n
Ultimate Medical Academy/Co
mplete Conference Management (CCM) is accredited as a provider of nursing
continuing professional education development by the American Nurses Crede
ntialing Center’s Commission on Accreditation.
\n
Awarded 1.0 contact
hour of continuing nursing education of RNs and APNs.
\n
DI
SCLOSURE POLICY STATEMENT
\n
In accordance with the Accredi
tation Council for Continuing Medical Education (ACCME) Standards for Comm
ercial Support\, educational programs sponsored by Med Learning Group must
demonstrate balance\, independence\, objectivity\, and scientific rigor.
All faculty\, authors\, editors\, staff\, and planning committee members p
articipating in an MLG-sponsored activity are required to disclose any rel
evant financial interest or other relationship with the manufacturer(s) of
any commercial product(s) and/or provider(s) of commercial services that
are discussed in an educational activity.
\n
DISCLOSURE OF C
ONFLICTS OF INTEREST
\n
Ryan Jacobs\, MD\,
receives consulting fees from Adaptive\, Genentech\, MorphoSys\, Secura B
io\, and TG Therapeutics\; he has served on the speaker’s bureau for AbbVi
e\, AstraZeneca\, Janssen\, Pharmacyclics\, Secura Bio\, and TG Therapeuti
cs. He has also received research funding from LOXO\, MEI Pharma\, Pharmac
yclics\, and Teneobio.
\n
CME Content Review
\n
The content of this activity was independently peer reviewed.
\nTh
e reviewer of this activity has nothing to disclose.
\n
CNE
Content Review
\n
The content of this activity was peer rev
iewed by a nurse reviewer.
\n
Douglas Cox\, MSN\, MHA\, RN
\nUlt
imate Medical Academy/CCM – Lead Nurse Planner
\n
The reviewer of thi
s activity has nothing to disclose.
\n
Staff Planners and Ma
nagers
\n
The staff\, planners\, and managers reported the
following financial relationships or relationships to products or devices
they or their spouse/life partner have with commercial interests related t
o the content of this CME/CE activity:
\n
\n- Matthew Frese\, MBA\
, General Manager of Med Learning Group\, has nothing to disclose.
\n<
li>Christina Gallo\, SVP\, Educational Development for Med Learning Group\
, has nothing to disclose.\n- James Seternus\, DO\, Medical & Scien
tific Services for Med Learning Group has nothing to disclose.
\n- L
auren Welch\, MA\, VP\, Accreditation and Outcomes for Med Learning Group\
, has nothing to disclose.
\n- Jessica McMullen\, MPH\, Program Mana
ger for Med Learning Group\, has nothing to disclose.
\n- Russie All
en\, Accreditation and Outcomes Manager for Med Learning Group\, has nothi
ng to disclose.
\n- Douglas Cox\, MSN\, MHA\, RN\, UMA/CCM – LNP\, h
as nothing to disclose.
\n
\n
DISCLOSURE OF UNLABELED U
SE
\n
Med Learning Group requires that faculty participatin
g in any CME activity disclose to the audience when discussing any unlabel
ed or investigational use of any commercial product or device not yet appr
oved for use in the United States. During this lecture\, the faculty may m
ention the use of medications for both FDA-approved and non-approved indic
ations.
\n
METHOD OF PARTICIPATION
\n
There a
re no fees for participating and receiving CME credit for this enduring ac
tivity. To receive CME/CNE credit participants must:
\n
\n- Read t
he CME/CNE information and faculty disclosures.
\n- Participate in t
he online activity.
\n- Complete the online post-test and evaluation
.
\n
\n
You will receive your certificate as a downloadable file
.
\n
DISCLAIMER
\n
Med Learning Group makes e
very effort to develop CME activities that are science based. This activit
y is designed for educational purposes. Participants have a responsibility
to use this information to enhance their professional development in an e
ffort to improve patient outcomes. Conclusions drawn by the participants s
hould be derived from careful consideration of all available scientific in
formation. The participant should use his/her clinical judgment\, knowledg
e\, experience\, and diagnostic decision making before applying any inform
ation\, whether provided here or by others\, for any professional use.
\n
For CME questions\, please contact Med Learning Group at info@medlearninggroup.com
a>
\n
Contact this CME provider at Med Learning Group for privacy and
confidentiality policy statement information at http://medlearninggroup.com/p
rivacy‐policy/
\n
AMERICANS WITH DISABILITIES ACT
\n
Staff will be glad to assist you with any special needs. Pleas
e contact Med Learning Group prior to participating at info@medlearninggroup.com
\n
RELEASE DATE: August 03\, 2022
\n
EXPIR
ATION DATE: August 03\, 2023
\n
\n
Copyright © 2022 Med Learning Group. All rights reserved. These
materials may be used for personal use only. Any rebroadcast\, distributi
on\, or reuse of this presentation or any part of it in any form for other
than personal use without the express written permission of Med Learning
Group is prohibited.
\n
\n
View Activity
\n
\n
\n\n
\n
\n
END:VEVENT
BEGIN:VEVENT
UID:ai1ec-205907@catalyst-hm.com
DTSTAMP:20240328T180159Z
CATEGORIES;LANGUAGE=en-US:Online Programs
CONTACT:
DESCRIPTION:Updates in Acute Myeloid Leukemia: What Are Best Practices for
Personalizing Therapy for Patients Within the Department of Veterans Affai
rs?\nVIEW ACTIVITY\nPROGRAM CHAIR\nCourtney D. DiNardo\, MD\, MSCE\nAssoci
ate Professor\, Department of Leukemia\nDivision of Cancer Medicine\nThe U
niversity of Texas MD Anderson Cancer Center\nHouston\, TX\nPROGRAM OVERVI
EW\nIn this enduring program\, we will discuss how healthcare providers wi
thin the Department of Veterans Affairs can improve their treatment of pat
ients with acute myeloid leukemia (AML) by providing updates on key biolog
ical features and biomarkers of AML to inform patient assessment with nove
l therapies. In addition\, we will review the latest data on AML managemen
t and challenges in effectively communicating the rationale for therapeuti
c decisions with patients and caregivers.\nTARGET AUDIENCE\nThis enduring
activity is intended for US-based hematologists\, medical oncologists\, an
d other healthcare providers involved in the management of patients with A
ML within the Department of Veterans Affairs.\nLEARNING OBJECTIVES\nUpon t
he completion of this program\, attendees should be able to:\n\nAnalyze cu
rrent data concerning molecular and genetic markers to inform therapeutic
decision-making in AML for patients within the Department of Veterans Affa
irs\nUnderstand the latest strategies for management of newly diagnosed an
d relapsed/refractory AML as informed by patient-specific features for pat
ients within the Department of Veterans Affairs\nEvaluate current data con
cerning management of adverse events and implementation of shared decision
-making to implement therapy in AML for patients within the Department of
Veterans Affairs\n\nACCREDITATION STATEMENT\nMed Learning Group is accredi
ted by the Accreditation Council for Continuing Medical Education (ACCME)
to provide continuing medical education for physicians. This CME activity
was planned and produced in accordance with the ACCME Essentials.\nPHYSICI
AN CREDIT DESIGNATION STATEMENT\nMed Learning Group designates this enduri
ng activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians s
hould claim only the credit commensurate with the extent of their particip
ation in the enduring activity.\nJOINT ACCREDITATION STATEMENT\nIn support
of improving patient care\, this activity has been planned and implemente
d by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited b
y the Accreditation Council for Continuing Medical Education (ACCME)\, the
Accreditation Council for Pharmacy Education (ACPE)\, and the American Nu
rses Credentialing Center (ANCC)\, to provide continuing education for the
health care team.\n\n\nNURSES (ANCC) CREDIT DESIGNATION\nAmedco LLC desig
nates this activity for a maximum of 1.0 ANCC contact hour.\nDISCLOSURE PO
LICY STATEMENT\nIn accordance with the Accreditation Council for Continuin
g Medical Education (ACCME) Standards for Commercial Support\, educational
programs sponsored by Med Learning Group must demonstrate balance\, indep
endence\, objectivity\, and scientific rigor. All faculty\, authors\, edit
ors\, staff\, and planning committee members participating in an MLG-spons
ored activity are required to disclose any relevant financial interest or
other relationship with the manufacturer(s) of any commercial product(s) a
nd/or provider(s) of commercial services that are discussed in an educatio
nal activity.\nDisclosure of Relevant Financial Relationship(s)\n\n\n\nSpe
aker\nRelationships\nManufacturer\n\n\nCourtney D. DiNardo\, MD\nConsultan
t\nAbbVie\, Bristol Myers Squibb\, Genmab\, Gilead Pharmaceuticals\, Glaxo
SmithKline\, ImmunoGen\, Jazz Pharmaceuticals\, Novartis\, Rigel\, and Ser
vier Laboratories\n\n\n\nContracted Research\nAbbVie\, Astex\, Bristol Mye
rs Squibb\, Cleave Therapeutics\, Foghorn Therapuetics\, Rigel Pharmaceuti
cals\, Immune-Onc Therapeutica\, Loxo Oncology\, and Servier Laboratorie\n
\n\n\nAll relevant financial relationships have been mitigated.\nCME Conte
nt Review\nThe content of this activity was independently peer reviewed.\n
The reviewer of this activity has nothing to disclose.\nCNE Content Review
\nThe content of this activity was peer reviewed by a nurse reviewer.\nThe
reviewer of this activity has nothing to disclose.\nStaff Planners and Ma
nagers\nThe staff\, planners\, and managers reported the following financi
al relationships or relationships to products or devices they have with in
eligible companies related to the content of this CME/CE activity:\n\nMatt
hew Frese\, MBA\, General Manager of Med Learning Group\, has nothing to d
isclose.\nChristina Gallo\, SVP\, Educational Development for Med Learning
Group\, has nothing to disclose.\nSharine Griggs\, Senior Program Manager
for Med Learning Group\, has nothing to disclose.\nSylvia Hanna\, Medical
Services for Med Learning Group\, has nothing to disclose.\nLauren Welch\
, MA\, VP\, Accreditation and Outcomes\, has nothing to disclose.\nRussie
Allen\, Accreditation and Outcomes Manager\, has nothing to disclose.\nEmm
anuella Foucault\, Program Coordinator\, has nothing to disclose.\n\nDISCL
OSURE OF UNLABELED USE\nMed Learning Group requires that faculty participa
ting in any CME activity disclose to the audience when discussing any unla
beled or investigational use of any commercial product or device not yet a
pproved for use in the United States. During this lecture\, the faculty ma
y mention the use of medications for both FDA-approved and non-approved in
dications.\nMETHOD OF PARTICIPATION\nThere are no fees for participating a
nd receiving CE credit for this activity.\nIn order to obtain your certifi
cate for the mentioned accreditation\, participants need to successfully c
omplete the associated pre/post activities and evaluation.\nYour certifica
te will be provided as a downloadable file.\nDISCLAIMER\nMed Learning Grou
p makes every effort to develop CME activities that are science-based. Thi
s activity is designed for educational purposes. Participants have a respo
nsibility to use this information to enhance their professional developmen
t in an effort to improve patient outcomes. Conclusions drawn by the parti
cipants should be derived from careful consideration of all available scie
ntific information. The participant should use his/her clinical judgment\,
knowledge\, experience\, and diagnostic decision-making expertise before
applying any information\, whether provided here or by others\, for any pr
ofessional use.\nFor CME questions\, please contact Med Learning Group at
info@medlearninggroup.com\nContact this CME provider at Med Learning Group
for privacy and confidentiality policy statement information at https://w
ww.medlearninggroup.com/privacy-policy/\nAMERICANS WITH DISABILITY ACT\nEv
ent staff will be glad to assist you with any special needs (eg\, physical
\, dietary\, etc.). Please contact Med Learning Group prior to the endurin
g activity at info@medlearninggroup.com\nRELEASED DATE: August 02\, 2023\n
EXPIRATION DATE: August 02\, 2024\n\nCopyright © 2023 Med Learning Group.
All rights reserved. These materials may be used for personal use only. An
y rebroadcast\, distribution\, or reuse of this presentation or any part o
f it in any form for other than personal use without the express written p
ermission of Med Learning Group is prohibited.\nVIEW ACTIVITY
DTSTART;TZID=America/New_York:20230802T075300
DTEND;TZID=America/New_York:20240802T085300
SEQUENCE:0
SUMMARY:Updates in Acute Myeloid Leukemia: What Are Best Practices for Pers
onalizing Therapy for Patients Within the Department of Veterans Affairs?
URL:https://catalyst-hm.com/event/updates-in-acute-myeloid-leukemia-what-ar
e-best-practices-for-personalizing-therapy-for-patients-within-the-departm
ent-of-veterans-affairs-2/
X-COST-TYPE:free
X-WP-IMAGES-URL:thumbnail\;https://catalyst-hm.com/wp-content/uploads/2023/
09/HM_42L_banner-150x150.jpg\;150\;150\;1\,medium\;https://catalyst-hm.com
/wp-content/uploads/2023/09/HM_42L_banner-300x46.jpg\;300\;46\;1\,large\;h
ttps://catalyst-hm.com/wp-content/uploads/2023/09/HM_42L_banner-1024x157.j
pg\;1024\;157\;1\,full\;https://catalyst-hm.com/wp-content/uploads/2023/09
/HM_42L_banner.jpg\;1220\;187\;
X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\n\\n\\n
div>
\n
\n
\n
Updates in Acute
Myeloid Leukemia: What Are Best Practices for Personalizing Therapy for P
atients Within the Department of Veterans Affairs?
\n
VIEW ACTIVITY
\n
PROGRAM CHAIR
strong>
\n
Courtney D. DiNardo\, MD\, MSCE
\nA
ssociate Professor\, Department of Leukemia
\nDivision of Cancer Medi
cine
\nThe University of Texas MD Anderson Cancer Center
\nHoust
on\, TX
\n
PROGRAM OVERVIEW
\n
In this enduri
ng program\, we will discuss how healthcare providers within the Departmen
t of Veterans Affairs can improve their treatment of patients with acute m
yeloid leukemia (AML) by providing updates on key biological features and
biomarkers of AML to inform patient assessment with novel therapies. In ad
dition\, we will review the latest data on AML management and challenges i
n effectively communicating the rationale for therapeutic decisions with p
atients and caregivers.
\n
TARGET AUDIENCE
\n
This enduring activity is intended for US-based hematologists\, medical o
ncologists\, and other healthcare providers involved in the management of
patients with AML within the Department of Veterans Affairs.
\n
LEARNING OBJECTIVES
\n
Upon the completion of this prog
ram\, attendees should be able to:
\n
\n- Analyze current data con
cerning molecular and genetic markers to inform therapeutic decision-makin
g in AML for patients within the Department of Veterans Affairs
\n-
Understand the latest strategies for management of newly diagnosed and rel
apsed/refractory AML as informed by patient-specific features for patients
within the Department of Veterans Affairs
\n- Evaluate current data
concerning management of adverse events and implementation of shared deci
sion-making to implement therapy in AML for patients within the Department
of Veterans Affairs
\n
\n
ACCREDITATION STATEMENT
\n
Med Learning Group is accredited by the Accreditation Counci
l for Continuing Medical Education (ACCME) to provide continuing medical e
ducation for physicians. This CME activity was planned and produced in acc
ordance with the ACCME Essentials.
\n
PHYSICIAN CREDIT DESIG
NATION STATEMENT
\n
Med Learning Group designates this endu
ring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the ex
tent of their participation in the enduring activity.
\n
JOI
NT ACCREDITATION STATEMENT
\n
In support of improving patient care\, this activity ha
s been planned and implemented by Amedco LLC and Med Learning Group. Amedc
o LLC is jointly accredited by the Accreditation Council for Continuing Me
dical Education (ACCME)\, the Accreditation Council for Pharmacy Education
(ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide
continuing education for the health care team.
\n
\n
\nNURSES (ANCC) CREDIT DESIGNATION
\n
Amedco LLC de
signates this activity for a maximum of 1.0 ANCC contact hour.
\n
DISCLOSURE POLICY STATEMENT
\n
In accordance with the
Accreditation Council for Continuing Medical Education (ACCME) Standards
for Commercial Support\, educational programs sponsored by Med Learning Gr
oup must demonstrate balance\, independence\, objectivity\, and scientific
rigor. All faculty\, authors\, editors\, staff\, and planning committee m
embers participating in an MLG-sponsored activity are required to disclose
any relevant financial interest or other relationship with the manufactur
er(s) of any commercial product(s) and/or provider(s) of commercial servic
es that are discussed in an educational activity.
\n
Disclos
ure of Relevant Financial Relationship(s)
\n
\n
\n\nSpeaker | \nRelationships | \nManufacturer | \n
\n\nCourtney D. DiNardo\, MD | \nConsultant
td>\n | AbbVie\, Bristol Myers Squibb\, Genmab\, Gilead Pharmaceuticals\,
GlaxoSmithKline\, ImmunoGen\, Jazz Pharmaceuticals\, Novartis\, Rigel\, a
nd Servier Laboratories | \n
\n\n | \nContract
ed Research | \nAbbVie\, Astex\, Bristol Myers Squibb\, Cle
ave Therapeutics\, Foghorn Therapuetics\, Rigel Pharmaceuticals\, Immune-O
nc Therapeutica\, Loxo Oncology\, and Servier Laboratorie | \n
\n\n
\n
All relevant financial relationships have
been mitigated.
\n
CME Content Review
\n
The content of this activity was independently peer reviewed.
\nThe reviewer of this activity has nothing to disclose.
\n
CNE Content Review
\n
The content of this activity was p
eer reviewed by a nurse reviewer.
\nThe reviewer of this activity has
nothing to disclose.
\n
Staff Planners and Managers
\n
The staff\, planners\, and managers reported the following fina
ncial relationships or relationships to products or devices they have with
ineligible companies related to the content of this CME/CE activity:
\n
\n- Matthew Frese\, MBA\, General Manager of Med Learning Group\,
has nothing to disclose.
\n- Christina Gallo\, SVP\, Educational Dev
elopment for Med Learning Group\, has nothing to disclose.
\n- Shari
ne Griggs\, Senior Program Manager for Med Learning Group\, has nothing to
disclose.
\n- Sylvia Hanna\, Medical Services for Med Learning Grou
p\, has nothing to disclose.
\n- Lauren Welch\, MA\, VP\, Accreditat
ion and Outcomes\, has nothing to disclose.
\n- Russie Allen\, Accre
ditation and Outcomes Manager\, has nothing to disclose.
\n- Emmanue
lla Foucault\, Program Coordinator\, has nothing to disclose.
\n
\n
DISCLOSURE OF UNLABELED USE
\n
Med Learning G
roup requires that faculty participating in any CME activity disclose to t
he audience when discussing any unlabeled or investigational use of any co
mmercial product or device not yet approved for use in the United States.
During this lecture\, the faculty may mention the use of medications for b
oth FDA-approved and non-approved indications.
\n
METHOD OF
PARTICIPATION
\n
There are no fees for participating and re
ceiving CE credit for this activity.
\n
In order to obtain your certi
ficate for the mentioned accreditation\, participants need to successfully
complete the associated pre/post activities and evaluation.
\n
Your
certificate will be provided as a downloadable file.
\n
DISC
LAIMER
\n
Med Learning Group makes every effort to develop
CME activities that are science-based. This activity is designed for educa
tional purposes. Participants have a responsibility to use this informatio
n to enhance their professional development in an effort to improve patien
t outcomes. Conclusions drawn by the participants should be derived from c
areful consideration of all available scientific information. The particip
ant should use his/her clinical judgment\, knowledge\, experience\, and di
agnostic decision-making expertise before applying any information\, wheth
er provided here or by others\, for any professional use.
\n
For CME
questions\, please contact Med Learning Group at info@medlearninggroup.com
\n
Co
ntact this CME provider at Med Learning Group for privacy and confidential
ity policy statement information at https://www.medlearninggroup.com/priv
acy-policy/
\n
AMERICANS WITH DISABILITY ACT\n
Event staff will be glad to assist you with any special needs (eg\,
physical\, dietary\, etc.). Please contact Med Learning Group prior to th
e enduring activity at info@medlearninggroup.com
\n
RELEASED DATE: August 02\, 2023
\nEXPIRATION DATE: August 02\,
2024
\n
\n
Copyright © 2023 Med Learning Group. All rights reserved. The
se materials may be used for personal use only. Any rebroadcast\, distribu
tion\, or reuse of this presentation or any part of it in any form for oth
er than personal use without the express written permission of Med Learnin
g Group is prohibited.
\n
VIEW ACTIVITY<
/a>
\n\n
\n
\n
END:VEVENT
BEGIN:VEVENT
UID:ai1ec-205901@catalyst-hm.com
DTSTAMP:20240328T180159Z
CATEGORIES;LANGUAGE=en-US:Online Programs
CONTACT:
DESCRIPTION:Improving Approaches to Care for Patients with Acute Myeloid Le
ukemia: Insights from the Experts to Navigate an Evolving Landscape\nVIEW
ACTIVITY\nPROGRAM CHAIR & FACULTY PRESENTER\nMichael R. Grunwald\, MD\, FA
CP\nChief\, Leukemia Division\nDirector\, Transplantation and Cellular The
rapy Program\nLevine Cancer Institute\, Atrium Health\nClinical Associate
Professor\, Wake Forest School of Medicine\nCharlotte\, NC\nPROGRAM OVERVI
EW\nThis enduring activity will explore the management of patients with ne
wly diagnosed and relapsed/refractory acute myeloid leukemia (AML) through
didactic slide review\, case study discussion\, and a robust Q&A session.
This program will address the role of genetic and molecular markers in tr
eatment selection as well as best practices for treatment of newly diagnos
ed\, relapsed/refractory\, and secondary AML. A summary of approaches to t
reatment-related adverse event recognition and mitigation will also be dis
cussed.\nTARGET AUDIENCE\nThis educational activity is intended for U.S.-b
ased hematologists\, medical oncologists\, and other healthcare providers
involved in the management of patients with AML.\nLEARNING OBJECTIVES\nUpo
n the completion of this program\, attendees should be able to:\n\nApprais
e current data concerning molecular and genetic markers to inform therapeu
tic decision-making in AML\nDescribe the latest strategies for management
of newly diagnosed and relapsed/refractory AML as informed by patient-spec
ific features\nAssess current data concerning management of adverse events
and implementation of shared decision-making to implement therapy in AML
\n\nACCREDITATION STATEMENT\nMed Learning Group is accredited by the Accre
ditation Council for Continuing Medical Education (ACCME) to provide conti
nuing medical education for physicians. This CME activity was planned and
produced in accordance with the ACCME Essentials.\nPHYSICIAN CREDIT DESIGN
ATION STATEMENT\nMed Learning Group designates this enduring activity for
a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only
the credit commensurate with the extent of their participation in the end
uring activity.\nJOINT ACCREDITATION STATEMENT\nIn support of improving pa
tient care\, this activity has been planned and implemented by Amedco LLC
and Med Learning Group. Amedco LLC is jointly accredited by the Accreditat
ion Council for Continuing Medical Education (ACCME)\, the Accreditation C
ouncil for Pharmacy Education (ACPE)\, and the American Nurses Credentiali
ng Center (ANCC)\, to provide continuing education for the healthcare team
.\n\n\nNURSES (ANCC) CREDIT DESIGNATION\nAmedco LLC designates this activi
ty for a maximum of 1.0 ANCC contact hour.\nDISCLOSURE POLICY STATEMENT\nI
n accordance with the Accreditation Council for Continuing Medical Educati
on (ACCME) Standards for Integrity and Independence in Accredited Continui
ng Education\, educational programs sponsored by Med Learning Group must d
emonstrate balance\, independence\, objectivity\, and scientific rigor. Al
l faculty\, authors\, editors\, staff\, and planning committee members par
ticipating in an MLG-sponsored activity are required to disclose any relev
ant financial interest or other relationship with the manufacturer(s) of a
ny commercial product(s) and/or provider(s) of commercial services that ar
e discussed in an educational activity.\nDISCLOSURE OF RELEVANT FINANCIAL
RELATIONSHIP(S)\n\n\n\nMichael R. Grunwald\, MD\, FACP\nConsulting fees: A
bbVie\, Amgen\, Astellas\, Blueprint Medicines\, Bristol Myers Squibb\, Ca
rdinal Health\, CTI BioPharma\, Daiichi Sankyo\, Genentech\, Gilead Scienc
es\, GSK/Sierra Oncology\, Incyte\, Invitae\, Jazz\, Novartis\, Ono Pharma
ceutical\, Pfizer\, Pharmacosmos\, Premier\, Servier/Agios\, and Stemline
Therapeutics.\nResearch support: Incyte and Janssen.\nStock ownership: Med
tronic.\n\n\n\nAll relevant financial relationships have been mitigated.\n
CME Content Review\nThe content of this activity was independently peer re
viewed.\nThe reviewer of this activity has nothing to disclose.\nCNE Conte
nt Review\nThe content of this activity was peer reviewed by a nurse revie
wer.\nThe reviewer of this activity has nothing to disclose.\nStaff Planne
rs and Managers\nThe staff\, planners\, and managers reported the followin
g financial relationships or relationships to products or devices they hav
e with ineligible companies related to the content of this CME/CE activity
:\n\nMatthew Frese\, MBA\, General Manager of Med Learning Group\, has not
hing to disclose.\nChristina Gallo\, SVP\, Educational Development for Med
Learning Group\, has nothing to disclose.\nLauren Welch\, MA\, VP\, Accre
ditation and Outcomes for Med Learning Group\, has nothing to disclose.\nT
ara Nelson-Mayfield\, MS\, Medical Director for Med Learning Group\, has n
othing to disclose.\nJessica McMullen\, MPH\, Program Manager for Med Lear
ning Group\, has nothing to disclose.\nLaura Aibara\, Program Coordinator\
, for Med Learning Group\, has nothing to disclose.\nDaniel DaSilva\, Accr
editation and Outcomes Coordinator\, has nothing to disclose.\n\nDISCLOSUR
E OF UNLABELED USE\nMed Learning Group requires that faculty participating
in any CME activity disclose to the audience when discussing any unlabele
d or investigational use of any commercial product or device not yet appro
ved for use in the United States. During this lecture\, the faculty may me
ntion the use of medications for both FDA-approved and non-approved indica
tions.\nMETHOD OF PARTICIPATION\nThere are no fees for participating and r
eceiving CE credit for this activity.\nIn order to obtain your certificate
for the mentioned accreditation\, participants need to successfully compl
ete the associated pre/post activities and evaluation.\nYour certificate w
ill be provided as a downloadable file.\nDISCLAIMER\nMed Learning Group ma
kes every effort to develop CME activities that are science based. This ac
tivity is designed for educational purposes. Participants have a responsib
ility to use this information to enhance their professional development in
an effort to improve patient outcomes. Conclusions drawn by the participa
nts should be derived from careful consideration of all available scientif
ic information. The participant should use his/her clinical judgment\, kno
wledge\, experience\, and diagnostic decision making before applying any i
nformation\, whether provided here or by others\, for any professional use
.\nFor CME questions\, please contact Med Learning Group at info@medlearni
nggroup.com\nContact this CME provider at Med Learning Group for privacy a
nd confidentiality policy statement information at https://www.medlearning
group.com/privacy-policy/\nAMERICANS WITH DISABILITIES ACT\nStaff will be
glad to assist you with any special needs. Please contact Med Learning Gro
up prior to participating at info@medlearninggroup.com\nRELEASED DATE: Aug
ust 14\, 2023\nEXPIRATION DATE: August 14\, 2024\n\nCopyright © 2023 Med L
earning Group. All rights reserved. These materials may be used for person
al use only. Any rebroadcast\, distribution\, or reuse of this presentatio
n or any part of it in any form for other than personal use without the ex
press written permission of Med Learning Group is prohibited.\nVIEW ACTIVI
TY
DTSTART;TZID=America/New_York:20230814T150200
DTEND;TZID=America/New_York:20240814T160200
SEQUENCE:0
SUMMARY:Improving Approaches to Care for Patients with Acute Myeloid Leukem
ia: Insights from the Experts to Navigate an Evolving Landscape
URL:https://catalyst-hm.com/event/improving-approaches-to-care-for-patients
-with-acute-myeloid-leukemia-insights-from-the-experts-to-navigate-an-evol
ving-landscape/
X-COST-TYPE:free
X-WP-IMAGES-URL:thumbnail\;https://catalyst-hm.com/wp-content/uploads/2023/
08/HM_44L_banner-150x150.jpg\;150\;150\;1\,medium\;https://catalyst-hm.com
/wp-content/uploads/2023/08/HM_44L_banner-300x46.jpg\;300\;46\;1\,large\;h
ttps://catalyst-hm.com/wp-content/uploads/2023/08/HM_44L_banner-1024x157.j
pg\;1024\;157\;1\,full\;https://catalyst-hm.com/wp-content/uploads/2023/08
/HM_44L_banner.jpg\;1220\;187\;
X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\n
\\n\\n
div>
\n
\n
\n
Improving Approaches to Care for Patients with Acute Myeloid
Leukemia: Insights from the Experts to Navigate an Evolving Landscape
\n
VIEW ACTIVITY
\n
P
ROGRAM CHAIR & FACULTY PRESENTER
\n
Michael R. Grun
wald\, MD\, FACP
\nChief\, Leukemia Division
\nDirector
\, Transplantation and Cellular Therapy Program
\nLevine Cancer Insti
tute\, Atrium Health
\nClinical Associate Professor\, Wake Forest Sch
ool of Medicine
\nCharlotte\, NC
\n
PROGRAM OVERVIEW
\n
This enduring activity will explore the management of pati
ents with newly diagnosed and relapsed/refractory acute myeloid leukemia (
AML) through didactic slide review\, case study discussion\, and a robust
Q&A session. This program will address the role of genetic and molecular m
arkers in treatment selection as well as best practices for treatment of n
ewly diagnosed\, relapsed/refractory\, and secondary AML. A summary of app
roaches to treatment-related adverse event recognition and mitigation will
also be discussed.
\n
TARGET AUDIENCE
\n
Thi
s educational activity is intended for U.S.-based hematologists\, medical
oncologists\, and other healthcare providers involved in the management of
patients with AML.
\n
LEARNING OBJECTIVES
\n
Upon the completion of this program\, attendees should be able to:
\n<
ul>\n
Appraise current data concerning molecular and genetic markers to
inform therapeutic decision-making in AML\n
Describe the latest s
trategies for management of newly diagnosed and relapsed/refractory AML as
informed by patient-specific features\n
Assess current data conce
rning management of adverse events and implementation of shared decision-m
aking to implement therapy in AML\n\n
ACCREDITATION S
TATEMENT
\n
Med Learning Group is accredited by the Accredi
tation Council for Continuing Medical Education (ACCME) to provide continu
ing medical education for physicians. This CME activity was planned and pr
oduced in accordance with the ACCME Essentials.
\n
PHYSICIAN
CREDIT DESIGNATION STATEMENT
\n
Med Learning Group designa
tes this enduring activity for a maximum of 1.0 AMA PRA Category 1 Cre
ditTM. Physicians should claim only the credit commensurat
e with the extent of their participation in the enduring activity.
\n
JOINT ACCREDITATION STATEMENT\nIn support of improving patient care\, this activity
has been planned and implemented by Amedco LLC and Med Learning Group. Am
edco LLC is jointly accredited by the Accreditation Council for Continuing
Medical Education (ACCME)\, the Accreditation Council for Pharmacy Educat
ion (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to prov
ide continuing education for the healthcare team.
\n\n
\nNURSES (ANCC) CREDIT DESIGNATION
\nAmedco LLC
designates this activity for a maximum of 1.0 ANCC contact hour.
\n
DISCLOSURE POLICY STATEMENT
\nIn accordance with t
he Accreditation Council for Continuing Medical Education (ACCME) Standard
s for Integrity and Independence in Accredited Continuing Education\, educ
ational programs sponsored by Med Learning Group must demonstrate balance\
, independence\, objectivity\, and scientific rigor. All faculty\, authors
\, editors\, staff\, and planning committee members participating in an ML
G-sponsored activity are required to disclose any relevant financial inter
est or other relationship with the manufacturer(s) of any commercial produ
ct(s) and/or provider(s) of commercial services that are discussed in an e
ducational activity.
\nDISCLOSURE OF RELEVANT FINANCIAL REL
ATIONSHIP(S)
\n\n\n\nMichael R.
Grunwald\, MD\, FACP | \nConsulting fees: AbbVie\, Amgen\, Astellas\, Blueprint Medicines\, Bristol Myers Squibb\,
Cardinal Health\, CTI BioPharma\, Daiichi Sankyo\, Genentech\, Gilead Scie
nces\, GSK/Sierra Oncology\, Incyte\, Invitae\, Jazz\, Novartis\, Ono Phar
maceutical\, Pfizer\, Pharmacosmos\, Premier\, Servier/Agios\, and Stemlin
e Therapeutics. \nResearch support: Incyte and Janss
en. \nStock ownership: Medtronic. | \n
\n\n
\nAll relevant financial relationships have be
en mitigated.
\nCME Content Review
h4>\n
The content of this activity was independently peer reviewed.
\nThe reviewer of this activity has nothing to disclose.
\nCNE Content Review
\nThe content of this activity was pee
r reviewed by a nurse reviewer.
\nThe reviewer of this activity has n
othing to disclose.
\nStaff Planners and Managers<
/h4>\n
The staff\, planners\, and managers reported the following financ
ial relationships or relationships to products or devices they have with i
neligible companies related to the content of this CME/CE activity:
\n<
ul>\nMatthew Frese\, MBA\, General Manager of Med Learning Group\, has
nothing to disclose.\nChristina Gallo\, SVP\, Educational Develo
pment for Med Learning Group\, has nothing to disclose.\nLauren W
elch\, MA\, VP\, Accreditation and Outcomes for Med Learning Group\, has n
othing to disclose.\nTara Nelson-Mayfield\, MS\, Medical Director
for Med Learning Group\, has nothing to disclose.\nJessica McMul
len\, MPH\, Program Manager for Med Learning Group\, has nothing to disclo
se.\nLaura Aibara\, Program Coordinator\, for Med Learning Group\
, has nothing to disclose.\nDaniel DaSilva\, Accreditation and Ou
tcomes Coordinator\, has nothing to disclose.\n\nDIS
CLOSURE OF UNLABELED USE
\nMed Learning Group requires tha
t faculty participating in any CME activity disclose to the audience when
discussing any unlabeled or investigational use of any commercial product
or device not yet approved for use in the United States. During this lectu
re\, the faculty may mention the use of medications for both FDA-approved
and non-approved indications.
\nMETHOD OF PARTICIPATION
\nThere are no fees for participating and receiving CE credit
for this activity.
\nIn order to obtain your certificate for the me
ntioned accreditation\, participants need to successfully complete the ass
ociated pre/post activities and evaluation.
\nYour certificate will
be provided as a downloadable file.
\nDISCLAIMER
h4>\n
Med Learning Group makes every effort to develop CME activities th
at are science based. This activity is designed for educational purposes.
Participants have a responsibility to use this information to enhance thei
r professional development in an effort to improve patient outcomes. Concl
usions drawn by the participants should be derived from careful considerat
ion of all available scientific information. The participant should use hi
s/her clinical judgment\, knowledge\, experience\, and diagnostic decision
making before applying any information\, whether provided here or by othe
rs\, for any professional use.
\nFor CME questions\, please contact
Med Learning Group at info@medlearninggroup.com
\nContact this CME provider at
Med Learning Group for privacy and confidentiality policy statement inform
ation at https://www.medlearninggroup.com/privacy-policy/
\nAMERICANS WITH DISABILITIES ACT
\nStaff will be glad
to assist you with any special needs. Please contact Med Learning Group p
rior to participating at info@medlearninggroup.com
\nRELEASED DATE: August 14\, 2023
\nEXPIRATION DATE: August 14\
, 2024
\n\nCopyright © 2023 Med Learning Group. All rights reserved. These materi
als may be used for personal use only. Any rebroadcast\, distribution\, or
reuse of this presentation or any part of it in any form for other than p
ersonal use without the express written permission of Med Learning Group i
s prohibited.
\nVIEW ACTIVITY
\n\n \n \n
END:VEVENT
BEGIN:VEVENT
UID:ai1ec-205909@catalyst-hm.com
DTSTAMP:20240328T180159Z
CATEGORIES;LANGUAGE=en-US:Online Programs
CONTACT:
DESCRIPTION:Approaches to Improving Care in Chronic Lymphocytic Leukemia Pa
tients Within the Department of Veterans Affairs: Insights from the Expert
s\nVIEW ACTIVITY\nPROGRAM CHAIR\nLori Leslie\, MD\nAssociate Professor of
Medicine\nHackensack Meridian Health School of Medicine\nDirector of CLL a
nd Indolent Lymphoma\nJohn Theurer Cancer Center\nHackensack\, NJ\nPROGRAM
OVERVIEW\nIn this activity we will discuss the relevance of specific gene
tic and molecular markers in Chronic Lymphocytic Leukemia (CLL)\, review t
he current evidence concerning the application of minimal residual disease
(MRD) monitoring\, and emerging strategies and combinations for CLL manag
ement in first-line and relapsed/refractory settings. Finally\, we will ex
amine the potential adverse events associated with CLL therapeutics\, incl
uding specific considerations with combination therapies.\nTARGET AUDIENCE
\nThis educational activity is intended for community hematologists\, onco
logists\, and clinicians involved in the assessment\, monitoring\, and tre
atment of CLL for patients within the Department of Veteran Affairs.\nLEAR
NING OBJECTIVES\nUpon the completion of this program\, attendees should be
able to:\n\nEvaluate the relevance of specific genetic and molecular mark
ers in CLL for patients within the Department of Veterans Affairs\nSummari
ze current evidence concerning the application of MRD monitoring in CLL fo
r patients within the Department of Veterans Affairs\nAssess current and e
merging strategies and combinations for CLL management in first-line and r
elapsed/refractory settings for patients within the Department of Veterans
Affairs\nExplain potential adverse events associated with CLL therapeutic
s and considerations with specific combinations for patients within the De
partment of Veterans Affairs\n\nACCREDITATION STATEMENT\nMed Learning Grou
p is accredited by the Accreditation Council for Continuing Medical Educat
ion (ACCME) to provide continuing medical education for physicians. This C
ME activity was planned and produced in accordance with the ACCME Essentia
ls.\nPHYSICIAN CREDIT DESIGNATION STATEMENT\nMed Learning Group designates
this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Physicians should claim only the credit commensurate with the extent of th
eir participation in the enduring activity.\nJoint Accreditation Statement
\nIn support of improving patient care\, this activity has been planned an
d implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly
accredited by the Accreditation Council for Continuing Medical Education (
ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the
American Nurses Credentialing Center (ANCC)\, to provide continuing educa
tion for the health care team.\n\n\nNurses (ANCC) Credit Designation\nAmed
co LLC designates this activity for a maximum of 1.0 ANCC contact hour.\nD
ISCLOSURE POLICY STATEMENT\nIn accordance with the Accreditation Council f
or Continuing Medical Education ACCME Standards for Integrity and Independ
ence in Accredited Continuing Education\, educational programs sponsored b
y Med Learning Group must demonstrate balance\, independence\, objectivity
\, and scientific rigor. All faculty\, authors\, editors\, staff\, and pla
nning committee members participating in an MLG-sponsored activity are req
uired to disclose any relevant financial interest or other relationship wi
th the manufacturer(s) of any commercial product(s) and/or provider(s) of
commercial services that are discussed in an educational activity.\nDisclo
sure of Relevant Financial Relationships\n\n\n\nSpeaker\nRelationships\nMa
nufacturer\n\n\nLori A Leslie\, MD\nConsultant\nADC Therapeutics\, Kite Gi
lead\, BeiGene\, Pharmacyclics Inc\, Merck Pharmacy\, Abbvie\, Genmab\, Se
aGen\, Janssen\, AstraZeneca\, and Eli Lily\n\n\nSpeakers Bureau\nKite Gil
ead\, Pharmacyclics\, Abbvie\, Genmab\, SeaGen\, Janssen\, Eli Lily\, Epiz
yme\, TG Therapeutics\, BeiGene\, and AstraZeneca\n\n\n\nAll relevant fina
ncial relationships have been mitigated.\nCME Content Review\nThe content
of this activity was independently peer reviewed.\nThe reviewer of this ac
tivity has nothing to disclose.\nCNE Content Review\nThe content of this a
ctivity was peer reviewed by a nurse reviewer.\nThe reviewer of this activ
ity has nothing to disclose.\nStaff Planners and Managers\nThe staff\, pla
nners\, and managers reported the following financial relationships or rel
ationships to products or devices they have with ineligible companies rela
ted to the content of this CME/CE activity:\n\nMatthew Frese\, MBA\, Gener
al Manager of Med Learning Group\, has nothing to disclose.\nChristina Gal
lo\, SVP\, Educational Development for Med Learning Group\, has nothing to
disclose.\nSharine Griggs\, Senior Program Manager for Med Learning Group
\, has nothing to disclose.\nSylvia Hanna\, Medical Services for Med Learn
ing Group\, has nothing to disclose.\nLauren Welch\, MA\, VP\, Accreditati
on and Outcomes\, has nothing to disclose.\nRussie Allen\, Accreditation a
nd Outcomes Manager for Med Learning Group\, has nothing to disclose.\nEmm
anuella Foucault\, Program Coordinator for Med Learning Group\, has nothin
g to disclose.\n\nDISCLOSURE OF UNLABELED USE\nMed Learning Group requires
that faculty participating in any CME activity disclose to the audience w
hen discussing any unlabeled or investigational use of any commercial prod
uct or device not yet approved for use in the United States. During this l
ecture\, the faculty may mention the use of medications for both FDA-appro
ved and non-approved indications.\nMETHOD OF PARTICIPATION\nThere are no f
ees for participating and receiving CE credit for this activity.\nIn order
to obtain your certificate for the mentioned accreditation\, participants
need to successfully complete the associated pre/post activities and eval
uation.\nYour certificate will be provided as a downloadable file.\nDISCLA
IMER\nMed Learning Group makes every effort to develop CME activities that
are science-based. This activity is designed for educational purposes. Pa
rticipants have a responsibility to use this information to enhance their
professional development in an effort to improve patient outcomes. Conclus
ions drawn by the participants should be derived from careful consideratio
n of all available scientific information. The participant should use his/
her clinical judgment\, knowledge\, experience\, and diagnostic decision-m
aking expertise before applying any information\, whether provided here or
by others\, for any professional use.\nFor CME questions\, please contact
Med Learning Group at info@medlearninggroup.com\nContact this CME provide
r at Med Learning Group for privacy and confidentiality policy statement i
nformation at www.medlearninggroup.com/privacy-policy/\nAMERICANS WITH DIS
ABILITY ACT\nEvent staff will be glad to assist you with any special needs
. Please contact Med Learning Group prior to the enduring activity at info
@medlearninggroup.com\nRELEASED DATE: August 31\, 2023\nEXPIRATION DATE: A
ugust 31\, 2024\n\nCopyright © 2023 Med Learning Group. All rights reserve
d. These materials may be used for personal use only. Any rebroadcast\, di
stribution\, or reuse of this presentation or any part of it in any form f
or other than personal use without the express written permission of Med L
earning Group is prohibited.\nVIEW ACTIVITY
DTSTART;TZID=America/New_York:20230831T080000
DTEND;TZID=America/New_York:20240831T090000
SEQUENCE:0
SUMMARY:Approaches to Improving Care in Chronic Lymphocytic Leukemia Patien
ts Within the Department of Veterans Affairs: Insights from the Experts
URL:https://catalyst-hm.com/event/approaches-to-improving-care-in-chronic-l
ymphocytic-leukemia-patients-within-the-department-of-veterans-affairs-ins
ights-from-the-experts-2/
X-COST-TYPE:free
X-WP-IMAGES-URL:thumbnail\;https://catalyst-hm.com/wp-content/uploads/2023/
09/HM_43L_banner_footer-150x150.jpg\;150\;150\;1\,medium\;https://catalyst
-hm.com/wp-content/uploads/2023/09/HM_43L_banner_footer-300x46.jpg\;300\;4
6\;1\,large\;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_43L_ban
ner_footer-1024x157.jpg\;1024\;157\;1\,full\;https://catalyst-hm.com/wp-co
ntent/uploads/2023/09/HM_43L_banner_footer.jpg\;1220\;187\;
X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\n
\\n\\n
\n
\n
\n
Approaches to Improving Care in Chronic Lymphocytic Leu
kemia Patients Within the Department of Veterans Affairs: Insights from th
e Experts
\n
VIEW ACTIVITY
\n
PROGRAM CHAIR
\n
Lori Leslie\, MD
\nAssociate Professor of Medicine
\nHackensack Meridia
n Health School of Medicine
\nDirector of CLL and Indolent Lymphoma\nJohn Theurer Cancer Center
\nHackensack\, NJ
\n
P
ROGRAM OVERVIEW
\n
In this activity we will discuss the rel
evance of specific genetic and molecular markers in Chronic Lymphocytic Le
ukemia (CLL)\, review the current evidence concerning the application of m
inimal residual disease (MRD) monitoring\, and emerging strategies and com
binations for CLL management in first-line and relapsed/refractory setting
s. Finally\, we will examine the potential adverse events associated with
CLL therapeutics\, including specific considerations with combination ther
apies.
\n
TARGET AUDIENCE
\n
This educational
activity is intended for community hematologists\, oncologists\, and clin
icians involved in the assessment\, monitoring\, and treatment of CLL for
patients within the Department of Veteran Affairs.
\n
LEARNI
NG OBJECTIVES
\n
Upon the completion of this program\, atte
ndees should be able to:
\n
\n- Evaluate the relevance of specific
genetic and molecular markers in CLL for patients within the Department o
f Veterans Affairs
\n- Summarize current evidence concerning the app
lication of MRD monitoring in CLL for patients within the Department of Ve
terans Affairs
\n- Assess current and emerging strategies and combin
ations for CLL management in first-line and relapsed/refractory settings f
or patients within the Department of Veterans Affairs
\n- Explain po
tential adverse events associated with CLL therapeutics and considerations
with specific combinations for patients within the Department of Veterans
Affairs
\n
\n
ACCREDITATION STATEMENT
\n<
p>Med Learning Group is accredited by the Accreditation Council for Contin
uing Medical Education (ACCME) to provide continuing medical education for
physicians. This CME activity was planned and produced in accordance with
the ACCME Essentials.\n
PHYSICIAN CREDIT DESIGNATION STATE
MENT
\n
Med Learning Group designates this enduring activit
y for a maximum of 1.0 AMA PRA Category 1 CreditTM. Ph
ysicians should claim only the credit commensurate with the extent of thei
r participation in the enduring activity.
\n
Joint Accredita
tion Statement
\n
In support of improving patient care\, this activity has been plann
ed and implemented by Amedco LLC and Med Learning Group. Amedco LLC is joi
ntly accredited by the Accreditation Council for Continuing Medical Educat
ion (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, an
d the American Nurses Credentialing Center (ANCC)\, to provide continuing
education for the health care team.
\n
\n
\nNu
rses (ANCC) Credit Designation
\n
Amedco LLC designates thi
s activity for a maximum of 1.0 ANCC contact hour.
\n
DISCLO
SURE POLICY STATEMENT
\n
In accordance with the Accreditati
on Council for Continuing Medical Education ACCME Standards for Integrity
and Independence in Accredited Continuing Education\, educational programs
sponsored by Med Learning Group must demonstrate balance\, independence\,
objectivity\, and scientific rigor. All faculty\, authors\, editors\, sta
ff\, and planning committee members participating in an MLG-sponsored acti
vity are required to disclose any relevant financial interest or other rel
ationship with the manufacturer(s) of any commercial product(s) and/or pro
vider(s) of commercial services that are discussed in an educational activ
ity.
\n
Disclosure of Relevant Financial Relationships
\n
\n\n\nSpeaker | \n<
strong>Relationships | \nManufacturer |
\n
\n\nLori A Leslie\, MD | \n<
td>Consultant\nADC Therapeutics\, Kite Gilead\,
BeiGene\, Pharmacyclics Inc\, Merck Pharmacy\, Abbvie\, Genmab\, SeaGen\,
Janssen\, AstraZeneca\, and Eli Lily | \n
\n\nSpeake
rs Bureau | \nKite Gilead\, Pharmacyclics\, Abbvie\, Genmab
\, SeaGen\, Janssen\, Eli Lily\, Epizyme\, TG Therapeutics\, BeiGene\, and
AstraZeneca | \n
\n\n
\n
All relevant
financial relationships have been mitigated.
\n
CME Content Review
\n
The content of this activity was in
dependently peer reviewed.
\nThe reviewer of this activity has nothin
g to disclose.
\n
CNE Content Review
\n
The c
ontent of this activity was peer reviewed by a nurse reviewer.
\nThe
reviewer of this activity has nothing to disclose.
\n
Staff
Planners and Managers
\n
The staff\, planners\, and manager
s reported the following financial relationships or relationships to produ
cts or devices they have with ineligible companies related to the content
of this CME/CE activity:
\n
\n- Matthew Frese\, MBA\, General Mana
ger of Med Learning Group\, has nothing to disclose.
\n- Christina G
allo\, SVP\, Educational Development for Med Learning Group\, has nothing
to disclose.
\n- Sharine Griggs\, Senior Program Manager for Med Lea
rning Group\, has nothing to disclose.
\n- Sylvia Hanna\, Medical Se
rvices for Med Learning Group\, has nothing to disclose.
\n- Lauren
Welch\, MA\, VP\, Accreditation and Outcomes\, has nothing to disclose.\n
- Russie Allen\, Accreditation and Outcomes Manager for Med Learning
Group\, has nothing to disclose.
\n- Emmanuella Foucault\, Program
Coordinator for Med Learning Group\, has nothing to disclose.
\n
\n
DISCLOSURE OF UNLABELED USE
\n
Med Learning G
roup requires that faculty participating in any CME activity disclose to t
he audience when discussing any unlabeled or investigational use of any co
mmercial product or device not yet approved for use in the United States.
During this lecture\, the faculty may mention the use of medications for b
oth FDA-approved and non-approved indications.
\n
METHOD OF
PARTICIPATION
\n
There are no fees for participating and re
ceiving CE credit for this activity.
\n
In order to obtain your certi
ficate for the mentioned accreditation\, participants need to successfully
complete the associated pre/post activities and evaluation.
\n
Your
certificate will be provided as a downloadable file.
\n
DISC
LAIMER
\n
Med Learning Group makes every effort to develop
CME activities that are science-based. This activity is designed for educa
tional purposes. Participants have a responsibility to use this informatio
n to enhance their professional development in an effort to improve patien
t outcomes. Conclusions drawn by the participants should be derived from c
areful consideration of all available scientific information. The particip
ant should use his/her clinical judgment\, knowledge\, experience\, and di
agnostic decision-making expertise before applying any information\, wheth
er provided here or by others\, for any professional use.
\n
For CME
questions\, please contact Med Learning Group at info@medlearninggroup.com
\n
Co
ntact this CME provider at Med Learning Group for privacy and confidential
ity policy statement information at www.medlearninggroup.com/privacy-polic
y/
\n
AMERICANS WITH DISABILITY ACT
\n
Ev
ent staff will be glad to assist you with any special needs. Please contac
t Med Learning Group prior to the enduring activity at info@medlearninggroup.com
\n
RELEASED DATE: August 31\, 2023
\nEXPIR
ATION DATE: August 31\, 2024
\n
\n
Copyright © 2023 Med Learning Group. All rights
reserved. These materials may be used for personal use only. Any rebroadca
st\, distribution\, or reuse of this presentation or any part of it in any
form for other than personal use without the express written permission o
f Med Learning Group is prohibited.
\n
<
a class='small-button smallblue' style='padding: 10px 20px\; color: #fffff
f\; background: #FFA300\; border-radius: 5px\; display: inline-block\;' hr
ef='https://mlgcme.com/programs/view/426' target='_blank' rel='noopener'>V
IEW ACTIVITY
\n\n
\n
\n
END:VEVENT
BEGIN:VEVENT
UID:ai1ec-205912@catalyst-hm.com
DTSTAMP:20240328T180159Z
CATEGORIES;LANGUAGE=en-US:Online Programs
CONTACT:
DESCRIPTION:Addressing Triple-Class Refractory Veterans Affairs Patients: T
reatment with Novel Mechanisms of Action – R/R Multiple Myeloma\nVIEW ACTI
VITY\nPROGRAM CHAIR & FACULTY PRESENTER\nKen H. Young\, MD\, PhD\nProfesso
r and Division Director\nDuke University Medical Center\nDuke Cancer Cente
r\nDurham\, NC\nPROGRAM OVERVIEW\nThis enduring program focuses on relapse
d/refractory multiple myeloma (R/RMM) and aims to help VA health care prof
essionals recognize overexpressed antigens that can serve as immunologic t
argets on malignant multiple myeloma plasma cells and how bispecific antib
odies can be leveraged as targeted therapy in R/RMM.\nTARGET AUDIENCE\nThi
s activity is designed to meet the educational needs of Veterans Affairs o
ncologists\, hematologists\, hematology pharmacists\, nurse practitioners\
, and physician’s assistants to ensure knowledge and confidence in the man
agement of relapsed/refractory multiple myeloma.\nLEARNING OBJECTIVES\nUpo
n the completion of this program\, attendees should be able to:\n\nDescrib
e the overexpressed antigens that are bispecific targets on malignant mult
iple myeloma plasma cells\nReview the pharmacodynamics of bispecific molec
ules in the relapsed/refractory setting of multiple myeloma\nEvaluate bisp
ecific antibody clinical trial findings for newly approved BCMA-targeted t
herapy in the treatment of relapsed/refractory multiple myeloma\n\nACCREDI
TATION STATEMENT\nMed Learning Group is accredited by the Accreditation Co
uncil for Continuing Medical Education (ACCME) to provide continuing medic
al education for physicians. This CME activity was planned and produced in
accordance with the ACCME Essentials.\nPHYSICIAN CREDIT DESIGNATION STATE
MENT\nMed Learning Group designates this enduring activity for a maximum o
f 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit
commensurate with the extent of their participation in the enduring activ
ity.\nJoint Accreditation Statement\nIn support of improving patient care\
, this activity has been planned and implemented by Amedco LLC and Med Lea
rning Group. Amedco LLC is jointly accredited by the Accreditation Council
for Continuing Medical Education (ACCME)\, the Accreditation Council for
Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (
ANCC)\, to provide continuing education for the healthcare team.\n\n \n \n
Nurses (ANCC) Credit Designation\nAmedco LLC designates this activity for
a maximum of 1.0 ANCC contact hour.\nDISCLOSURE POLICY STATEMENT\nIn accor
dance with the Accreditation Council for Continuing Medical Education (ACC
ME) Standards for Integrity and Independence in Accredited Continuing Educ
ation\, educational programs sponsored by Med Learning Group must demonstr
ate balance\, independence\, objectivity\, and scientific rigor. All facul
ty\, authors\, editors\, staff\, and planning committee members participat
ing in an MLG-sponsored activity are required to disclose any relevant fin
ancial interest or other relationship with the manufacturer(s) of any comm
ercial product(s) and/or provider(s) of commercial services that are discu
ssed in an educational activity.\nDISCLOSURE OF RELEVANT FINANCIAL RELATIO
NSHIP(S)\n\n\n\nFaculty Member\nRelationships\n\n\nKen H. Young\, MD\, PhD
\nDr. Young has nothing to disclose.\n\n\n\nAll relevant financial relatio
nships have been mitigated.\nCME Content Review\nThe content of this activ
ity was independently peer reviewed.\nThe reviewer of this activity has no
thing to disclose.\nCNE Content Review\nThe content of this activity was p
eer reviewed by a nurse reviewer.\nThe reviewer of this activity has nothi
ng to disclose.\nStaff Planners and Managers\nThe staff\, planners\, and m
anagers reported the following financial relationships or relationships to
products or devices they have with ineligible companies related to the co
ntent of this CME/CE activity:\n\nMatthew Frese\, MBA\, General Manager of
Med Learning Group\, has nothing to disclose.\nChristina Gallo\, SVP\, Ed
ucational Development for Med Learning Group\, has nothing to disclose.\nL
auren Welch\, MA\, VP\, Accreditation and Outcomes for Med Learning Group\
, has nothing to disclose.\nNicole Longo\, DO\, FACOI\, VP Med/Sci Service
s & Learner Engagement for Med Learning Group\, has nothing to disclose.\n
Payal Patel\, PharmD\, Medical Director for Med Learning Group\, has nothi
ng to disclose.\nJessica McMullen\, MPH\, Senior Program Manager for Med L
earning Group\, has nothing to disclose.\nLaura Aibara\, Program Coordinat
or\, for Med Learning Group\, has nothing to disclose.\nDaniel DaSilva\, A
ccreditation and Outcomes Coordinator\, has nothing to disclose.\n\nDISCLO
SURE OF UNLABELED USE\nMed Learning Group requires that faculty participat
ing in any CME activity disclose to the audience when discussing any unlab
eled or investigational use of any commercial product or device not yet ap
proved for use in the United States. During this lecture\, the faculty may
mention the use of medications for both FDA-approved and non-approved ind
ications.\nMETHOD OF PARTICIPATION\nThere are no fees for participating an
d receiving CE credit for this activity.\nIn order to obtain your certific
ate for the mentioned accreditation\, participants need to successfully co
mplete the associated pre/post activities and evaluation.\nYour certificat
e will be provided as a downloadable file.\nDISCLAIMER\nMed Learning Group
makes every effort to develop CME activities that are science based. This
activity is designed for educational purposes. Participants have a respon
sibility to use this information to enhance their professional development
in an effort to improve patient outcomes. Conclusions drawn by the partic
ipants should be derived from careful consideration of all available scien
tific information. The participant should use his/her clinical judgment\,
knowledge\, experience\, and diagnostic decision making before applying an
y information\, whether provided here or by others\, for any professional
use.\nFor CME questions\, please contact Med Learning Group at info@medlea
rninggroup.com\nContact this CME provider at Med Learning Group for privac
y and confidentiality policy statement information at www.medlearninggroup
.com/privacy-policy/\nAMERICANS WITH DISABILITY ACT\nEvent staff will be g
lad to assist you with any special needs. Please contact Med Learning Grou
p prior to the enduring activity at info@medlearninggroup.com\nRELEASED DA
TE: September 25\, 2023\nEXPIRATION DATE: September 25\, 2024\n\nCopyright
© 2023 Med Learning Group. All rights reserved. These materials may be us
ed for personal use only. Any rebroadcast\, distribution\, or reuse of thi
s presentation or any part of it in any form for other than personal use w
ithout the express written permission of Med Learning Group is prohibited.
\nVIEW ACTIVITY
DTSTART;TZID=America/New_York:20230925T220700
DTEND;TZID=America/New_York:20240925T230700
SEQUENCE:0
SUMMARY:Addressing Triple-Class Refractory Veterans Affairs Patients: Treat
ment with Novel Mechanisms of Action – R/R Multiple Myeloma
URL:https://catalyst-hm.com/event/addressing-triple-class-refractory-vetera
ns-affairs-patients-treatment-with-novel-mechanisms-of-action-r-r-multiple
-myeloma/
X-COST-TYPE:free
X-WP-IMAGES-URL:thumbnail\;https://catalyst-hm.com/wp-content/uploads/2023/
09/HM_47L_banner_rev-150x150.jpg\;150\;150\;1\,medium\;https://catalyst-hm
.com/wp-content/uploads/2023/09/HM_47L_banner_rev-300x46.jpg\;300\;46\;1\,
large\;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_47L_banner_re
v-1024x157.jpg\;1024\;157\;1\,full\;https://catalyst-hm.com/wp-content/upl
oads/2023/09/HM_47L_banner_rev.jpg\;1220\;187\;
X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\n
\\n\\n
\n
\n
\n
Addressing Triple-Class Refractory Veterans Affairs Patients: Treatmen
t with Novel Mechanisms of Action – R/R Multiple Myeloma
\n
VIEW ACTIVITY
\n
PROGRAM C
HAIR & FACULTY PRESENTER
\n
Ken H. Young\, MD\, PhD
\nProfessor and Division Director
\nDuke University Me
dical Center
\nDuke Cancer Center
\nDurham\, NC
\n
PROGRAM OVERVIEW
\n
This enduring program focuses on relap
sed/refractory multiple myeloma (R/RMM) and aims to help VA health care pr
ofessionals recognize overexpressed antigens that can serve as immunologic
targets on malignant multiple myeloma plasma cells and how bispecific ant
ibodies can be leveraged as targeted therapy in R/RMM.
\n
TA
RGET AUDIENCE
\n
This activity is designed to meet the educ
ational needs of Veterans Affairs oncologists\, hematologists\, hematology
pharmacists\, nurse practitioners\, and physician’s assistants to ensure
knowledge and confidence in the management of relapsed/refractory multiple
myeloma.
\n
LEARNING OBJECTIVES
\n
Upon the
completion of this program\, attendees should be able to:
\n
\n- D
escribe the overexpressed antigens that are bispecific targets on malignan
t multiple myeloma plasma cells
\n- Review the pharmacodynamics of b
ispecific molecules in the relapsed/refractory setting of multiple myeloma
\n- Evaluate bispecific antibody clinical trial findings for newly
approved BCMA-targeted therapy in the treatment of relapsed/refractory mul
tiple myeloma
\n
\n
ACCREDITATION STATEMENT\n
Med Learning Group is accredited by the Accreditation Council for C
ontinuing Medical Education (ACCME) to provide continuing medical educatio
n for physicians. This CME activity was planned and produced in accordance
with the ACCME Essentials.
\n
PHYSICIAN CREDIT DESIGNATION
STATEMENT
\n
Med Learning Group designates this enduring ac
tivity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of
their participation in the enduring activity.
\n
Joint Accr
editation Statement
\n
In support of improving patient care\, this activity has been
planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC i
s jointly accredited by the Accreditation Council for Continuing Medical E
ducation (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)
\, and the American Nurses Credentialing Center (ANCC)\, to provide contin
uing education for the healthcare team.
\n
\n
\n
\n
Nurses (ANCC) Credit Designation
\n
Amedco LL
C designates this activity for a maximum of 1.0 ANCC contact hour.
\n
DISCLOSURE POLICY STATEMENT\nIn accordance with
the Accreditation Council for Continuing Medical Education (ACCME) Standa
rds for Integrity and Independence in Accredited Continuing Education\, ed
ucational programs sponsored by Med Learning Group must demonstrate balanc
e\, independence\, objectivity\, and scientific rigor. All faculty\, autho
rs\, editors\, staff\, and planning committee members participating in an
MLG-sponsored activity are required to disclose any relevant financial int
erest or other relationship with the manufacturer(s) of any commercial pro
duct(s) and/or provider(s) of commercial services that are discussed in an
educational activity.
\nDISCLOSURE OF RELEVANT FINANCIAL R
ELATIONSHIP(S)
\n\n\n\nFaculty Member | \nRelationships | \n
\n\nKen H. Young\
, MD\, PhD | \nDr. Young has nothing to disclose. | \n
\n\n<
/table>\nAll relevant financial relationships have been mit
igated.
\nCME Content Review
\n<
p>The content of this activity was independently peer reviewed.
\nThe
reviewer of this activity has nothing to disclose.\nCNE C
ontent Review
\nThe content of this activity was peer revi
ewed by a nurse reviewer.
\nThe reviewer of this activity has nothing
to disclose.
\nStaff Planners and Managers
\n
The staff\, planners\, and managers reported the following financial re
lationships or relationships to products or devices they have with ineligi
ble companies related to the content of this CME/CE activity:
\n\n<
li>Matthew Frese\, MBA\, General Manager of Med Learning Group\, has nothi
ng to disclose.\n- Christina Gallo\, SVP\, Educational Development
for Med Learning Group\, has nothing to disclose.
\n- Lauren Welch\,
MA\, VP\, Accreditation and Outcomes for Med Learning Group\, has nothing
to disclose.
\n- Nicole Longo\, DO\, FACOI\, VP Med/Sci Services &
Learner Engagement for Med Learning Group\, has nothing to disclose.
\n- Payal Patel\, PharmD\, Medical Director for Med Learning Group\, has
nothing to disclose.
\n- Jessica McMullen\, MPH\, Senior Program Ma
nager for Med Learning Group\, has nothing to disclose.
\n- Laura Ai
bara\, Program Coordinator\, for Med Learning Group\, has nothing to discl
ose.
\n- Daniel DaSilva\, Accreditation and Outcomes Coordinator\, h
as nothing to disclose.
\n
\nDISCLOSURE OF UNLABELED U
SE
\nMed Learning Group requires that faculty participatin
g in any CME activity disclose to the audience when discussing any unlabel
ed or investigational use of any commercial product or device not yet appr
oved for use in the United States. During this lecture\, the faculty may m
ention the use of medications for both FDA-approved and non-approved indic
ations.
\nMETHOD OF PARTICIPATION
\nThere a
re no fees for participating and receiving CE credit for this activity.
\nIn order to obtain your certificate for the mentioned accreditation\
, participants need to successfully complete the associated pre/post activ
ities and evaluation.
\nYour certificate will be provided as a downl
oadable file.
\nDISCLAIMER
\nMed Learning G
roup makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a re
sponsibility to use this information to enhance their professional develop
ment in an effort to improve patient outcomes. Conclusions drawn by the pa
rticipants should be derived from careful consideration of all available s
cientific information. The participant should use his/her clinical judgmen
t\, knowledge\, experience\, and diagnostic decision making before applyin
g any information\, whether provided here or by others\, for any professio
nal use.
\nFor CME questions\, please contact Med Learning Group at
info@medlearnin
ggroup.com
\nContact this CME provider at Med Learning Group for
privacy and confidentiality policy statement information at www.medlearni
nggroup.com/privacy-policy/
\nAMERICANS WITH DISABILITY
ACT
\nEvent staff will be glad to assist you with any spe
cial needs. Please contact Med Learning Group prior to the enduring activi
ty at info@medl
earninggroup.com
\nRELEASED DATE: September 25\
, 2023
\nEXPIRATION DATE: September 25\, 2024
\n<
p>\nCopyright © 2
023 Med Learning Group. All rights reserved. These materials may be used f
or personal use only. Any rebroadcast\, distribution\, or reuse of this pr
esentation or any part of it in any form for other than personal use witho
ut the express written permission of Med Learning Group is prohibited.
\nVIEW ACTIVITY
\n\n \n
\n
END:VEVENT
BEGIN:VEVENT
UID:ai1ec-205917@catalyst-hm.com
DTSTAMP:20240328T180159Z
CATEGORIES;LANGUAGE=en-US:Online Programs
CONTACT:
DESCRIPTION:CATALYST: Optimizing Clinical Decisions in Hematologic Malignan
cies Through Shared Decision-Making — Focus on CLL and AML\nVIEW ACTIVITY
\n\n\nFACULTY\nMichael R. Grunwald\, MD\, FACP \nChief\, Leukemia Division
\nDirector\, Transplantation and Cellular Therapy Program\nLevine Cancer I
nstitute\, Atrium Health\nClinical Associate Professor\, Wake Forest Schoo
l of Medicine\nCharlotte\, NC\nRyan Jacobs\, MD\nClinical Director\nDivisi
on of Lymphoma Therapy & Research\nDepartment of Hematologic Oncology\, BM
T & Blood Disorders\nLevine Cancer Institute/Atrium Health\nCharlotte\, NC
\nPROGRAM OVERVIEW\nThis enduring program is designed for US-based hematol
ogists\, medical oncologists\, and other healthcare providers involved in
the management of patients with CLL and/or AML and will enhance our target
healthcare practitioner’s (HCP) ability to: appraise the latest molecular
and genetic data in AML and CLL management\; justify best practices in ma
nagement of newly diagnosed relapsed/refractory AML and CLL considering sp
ecific patient-related and disease-related factors to inform management\;
and assess potential adverse events concerning AML and CLL to ensure optim
al monitoring and management.\nTARGET AUDIENCE\nThis multi-modular educati
onal initiative is intended for US-based hematologists\, medical oncologis
ts\, and other healthcare providers involved in the management of patients
with CLL and/or AML.\nLEARNING OBJECTIVES\nAfter attending the meeting\,
participants should be better able to:\n\nAppraise the latest molecular an
d genetic data in AML and CLL management\nJustify best practices in manage
ment of newly diagnosed and relapsed/refractory AML and CLL considering sp
ecific patient-related and disease-related factors to inform management\nA
ssess potential adverse events concerning AML and CLL to ensure optimal mo
nitoring and management\n\nACCREDITATION STATEMENT\nMed Learning Group is
accredited by the Accreditation Council for Continuing Medical Education (
ACCME) to provide continuing medical education for physicians. This CME ac
tivity was planned and produced in accordance with the ACCME Essentials.\n
PHYSICIAN CREDIT DESIGNATION STATEMENT\nMed Learning Group designates this
enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Phys
icians should claim only the credit commensurate with the extent of their
participation in the enduring activity.\nJOINT ACCREDITATION STATEMENT\nIn
support of improving patient care\, this activity has been planned and im
plemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accr
edited by the Accreditation Council for Continuing Medical Education (ACCM
E)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the Ame
rican Nurses Credentialing Center (ANCC)\, to provide continuing education
for the healthcare team.\n\nNURSES (ANCC) CREDIT DESIGNATION\nAmedco LLC
designates this activity for a maximum of 2.0 ANCC contact hours.\nDISCLOS
URE POLICY STATEMENT\nIn accordance with the Accreditation Council for Con
tinuing Medical Education (ACCME) Standards for Integrity and Independence
in Accredited Continuing Education\, educational programs sponsored by Me
d Learning Group must demonstrate balance\, independence\, objectivity\, a
nd scientific rigor. All faculty\, authors\, editors\, staff\, and plannin
g committee members participating in an MLG-sponsored activity are require
d to disclose any relevant financial interest or other relationship with t
he manufacturer(s) of any commercial product(s) and/or provider(s) of comm
ercial services that are discussed in an educational activity.\nDISCLOSURE
OF RELEVANT FINANCIAL RELATIONSHIP(S)\n\n\n\nMichael R. Grunwald\, MD\, F
ACP\nConsulting fees: AbbVie\, Amgen\, Astellas\, Blueprint Medicines\, Br
istol Myers Squibb\, Cardinal Health\, CTI BioPharma\, Daiichi Sankyo\, Ge
nentech\, Gilead Sciences\, GSK/Sierra Oncology\, Incyte\, Invitae\, Jazz\
, Novartis\, Ono Pharmaceutical\, Pfizer\, Pharmacosmos\, Premier\, Servie
r/Agios\, and Stemline Therapeutics.\nResearch support: Incyte and Janssen
.\nStock ownership: Medtronic.\n\n\nRyan Jacobs\, MD\nSpeakers bureau for
AbbVie\, AstraZeneca\, Beigene\, Janssen\, Pharmacyclics and SecuraBio. C
onsultancy/advisory role for AbbVie\, AstraZeneca\, Beigene\, Genentech\,
Janssen\, SecuraBio\, and Pharmacyclics. Research funding from AbbVie\, A
straZeneca\, LOXO Oncology\, Pharmacyclics\, Teneobio.\n\n\n\nAll relevant
financial relationships have been mitigated.\nCME Content Review \nThe co
ntent of this activity was independently peer reviewed.\nThe reviewer of t
his activity has nothing to disclose.\nCNE Content Review \nThe content of
this activity was peer reviewed by a nurse reviewer.\nThe reviewer of thi
s activity has nothing to disclose.\nStaff Planners and Managers\nThe staf
f\, planners\, and managers reported the following financial relationships
or relationships to products or devices they have with ineligible compani
es related to the content of this activity:\n\nMatthew Frese\, MBA\, Gener
al Manager of Med Learning Group\, has nothing to disclose.\nChristina Gal
lo\, SVP\, Educational Development for Med Learning Group\, has nothing to
disclose.\nPayal Patel\, PharmD\, Medical Director for Med Learning Group
\, has nothing to disclose.\nLauren Welch\, MA\, VP\, Accreditation and Ou
tcomes for Med Learning Group\, has nothing to disclose.\nAimee Meissner\,
Accreditation and Outcomes Coordinator for Med Learning Group\, has nothi
ng to disclose.\nFelecia Beachum\, Sr. Program Manager for Med Learning Gr
oup\, has nothing to disclose.\nNaomi De Brito\, Associate Program Manager
for Med Learning Group\, has nothing to disclose.\n\nDISCLOSURE OF UNLABE
LED USE\nMed Learning Group requires that faculty participating in any CME
activity disclose to the audience when discussing any unlabeled or invest
igational use of any commercial product or device not yet approved for use
in the United States.\nDuring this lecture\, the faculty may mention the
use of medications for both FDA-approved and non-approved indications.\nME
THOD OF PARTICIPATION\nThere are no fees for participating and receiving C
E credit for this activity.\nIn order to obtain your certificate for the m
entioned accreditation\, participants need to successfully complete the as
sociated pre/post activities and evaluation.\nYour certificate will be pro
vided as a downloadable file.\nDISCLAIMER \nMed Learning Group makes every
effort to develop CME activities that are science based. This activity is
designed for educational purposes. Participants have a responsibility to
use this information to enhance their professional development in an effor
t to improve patient outcomes. Conclusions drawn by the participants shoul
d be derived from careful consideration of all available scientific inform
ation. The participant should use his/her clinical judgment\, knowledge\,
experience\, and diagnostic decision making before applying any informatio
n\, whether provided here or by others\, for any professional use.\nFor CM
E questions\, please contact Med Learning Group at info@medlearninggroup.c
om\nContact this CME provider at Med Learning Group for privacy and confid
entiality policy statement information at https://medlearninggroup.com/pri
vacy-policy/\nAMERICANS WITH DISABILITIES ACT\nEvent staff will be glad to
assist you with any special needs. Please contact Med Learning Group prio
r to participating at info@medlearninggroup.com\nRELEASED DATE: November 3
0\, 2023\nEXPIRATION DATE: November 30\, 2024\n\nCopyright © 2023 Med Lear
ning Group. All rights reserved. These materials may be used for personal
use only. Any rebroadcast\, distribution\, or reuse of this presentation o
r any part of it in any form for other than personal use without the expre
ss written permission of Med Learning Group is prohibited.\n\n\nVIEW ACTIV
ITY
DTSTART;TZID=America/New_York:20231130T172100
DTEND;TZID=America/New_York:20241130T182100
SEQUENCE:0
SUMMARY:CATALYST: Optimizing Clinical Decisions in Hematologic Malignancies
Through Shared Decision-Making — Focus on CLL and AML
URL:https://catalyst-hm.com/event/catalyst-optimizing-clinical-decisions-in
-hematologic-malignancies-through-shared-decision-making-focus-on-cll-and-
aml/
X-COST-TYPE:free
X-WP-IMAGES-URL:thumbnail\;https://catalyst-hm.com/wp-content/uploads/2023/
12/HM_49_01L_banner_footer-150x150.jpg\;150\;150\;1\,medium\;https://catal
yst-hm.com/wp-content/uploads/2023/12/HM_49_01L_banner_footer-300x46.jpg\;
300\;46\;1\,large\;https://catalyst-hm.com/wp-content/uploads/2023/12/HM_4
9_01L_banner_footer-1024x157.jpg\;1024\;157\;1\,full\;https://catalyst-hm.
com/wp-content/uploads/2023/12/HM_49_01L_banner_footer.jpg\;1906\;292\;
X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\n\\n\\n\n
\n
\n
CATALYST: Optimizing Clinical Decisions
in Hematologic Malignancies Through Shared Decision-Making — Focus on CLL
and AML
\n
VIEW ACTIVITY<
/p>\n
\n
\n
FACULTY
\n
Michael R. Grunwald\, MD\, FACP
\nChief\, Leu
kemia Division
\nDirector\, Transplantation and Cellular Therapy Prog
ram
\nLevine Cancer Institute\, Atrium Health
\nClinical Associa
te Professor\, Wake Forest School of Medicine
\nCharlotte\, NC
\n<
p>
Ryan Jacobs\, MD\nClinical Director
\nDivisi
on of Lymphoma Therapy & Research
\nDepartment of Hematologic Oncolog
y\, BMT & Blood Disorders
\nLevine Cancer Institute/Atrium Health
\nCharlotte\, NC\n
PROGRAM OVERVIEW
\n
Thi
s enduring program is designed for US-based hematologists\, medical oncolo
gists\, and other healthcare providers involved in the management of patie
nts with CLL and/or AML and will enhance our target healthcare practitione
r’s (HCP) ability to: appraise the latest molecular and genetic data in AM
L and CLL management\; justify best practices in management of newly diagn
osed relapsed/refractory AML and CLL considering specific patient-related
and disease-related factors to inform management\; and assess potential ad
verse events concerning AML and CLL to ensure optimal monitoring and manag
ement.
\n
TARGET AUDIENCE
\n
This multi-modul
ar educational initiative is intended for US-based hematologists\, medical
oncologists\, and other healthcare providers involved in the management o
f patients with CLL and/or AML.
\n
LEARNING OBJECTIVES
\n
After attending the meeting\, participants should be better a
ble to:
\n
\n- Appraise the latest molecular and genetic data in A
ML and CLL management
\n- Justify best practices in management of ne
wly diagnosed and relapsed/refractory AML and CLL considering specific pat
ient-related and disease-related factors to inform management
\n- As
sess potential adverse events concerning AML and CLL to ensure optimal mon
itoring and management
\n
\n
ACCREDITATION STATEMENT
\n
Med Learning Group is accredited by the Accreditation Coun
cil for Continuing Medical Education (ACCME) to provide continuing medical
education for physicians. This CME activity was planned and produced in a
ccordance with the ACCME Essentials.
\n
PHYSICIAN CREDIT DES
IGNATION STATEMENT
\n
Med Learning Group designates this en
during activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM
. Physicians should claim only the credit commensurate with the
extent of their participation in the enduring activity.
\n
JOINT ACCREDITATION STATEMENT
\n
In support of improving patient care\, this activity
has been planned and implemented by Amedco LLC and Med Learning Group. Am
edco LLC is jointly accredited by the Accreditation Council for Continuing
Medical Education (ACCME)\, the Accreditation Council for Pharmacy Educat
ion (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to prov
ide continuing education for the healthcare team.
\n
\nNURSES (ANCC) CREDIT DESIGNATION
\n
Amedco LLC designates
this activity for a maximum of 2.0 ANCC contact hours.
\n
D
ISCLOSURE POLICY STATEMENT
\n
In accordance with the Accred
itation Council for Continuing Medical Education (ACCME) Standards for Int
egrity and Independence in Accredited Continuing Education\, educational p
rograms sponsored by Med Learning Group must demonstrate balance\, indepen
dence\, objectivity\, and scientific rigor. All faculty\, authors\, editor
s\, staff\, and planning committee members participating in an MLG-sponsor
ed activity are required to disclose any relevant financial interest or ot
her relationship with the manufacturer(s) of any commercial product(s) and
/or provider(s) of commercial services that are discussed in an educationa
l activity.
\n
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP
(S)
\n
\n\n\nMichael R. Grunwald
\, MD\, FACP | \nConsulting fees: AbbVie\,
Amgen\, Astellas\, Blueprint Medicines\, Bristol Myers Squibb\, Cardinal
Health\, CTI BioPharma\, Daiichi Sankyo\, Genentech\, Gilead Sciences\, GS
K/Sierra Oncology\, Incyte\, Invitae\, Jazz\, Novartis\, Ono Pharmaceutica
l\, Pfizer\, Pharmacosmos\, Premier\, Servier/Agios\, and Stemline Therape
utics. \nResearch support: Incyte and Janssen.
\nStock ownership: Medtronic. | \n
\n\nRyan Jacobs\, MD | \nSpeakers bureau for AbbVie\, Astra
Zeneca\, Beigene\, Janssen\, Pharmacyclics and SecuraBio. Consult
ancy/advisory role for AbbVie\, AstraZeneca\, Beigene\, Genentech
\, Janssen\, SecuraBio\, and Pharmacyclics. Research funding from AbbVie\, AstraZeneca\, LOXO Oncology\, Pharmacyclics\, Teneobio.
| \n
\n\n
\n
All relevant financial re
lationships have been mitigated.
\n
CME Conten
t Review
\n
The content of this activity was independently
peer reviewed.
\nThe reviewer of this activity has nothing to disclo
se.
\n
CNE Content Review
\n
The content of
this activity was peer reviewed by a nurse reviewer.
\nThe reviewer o
f this activity has nothing to disclose.
\n
Staff Planners a
nd Managers
\n
The staff\, planners\, and managers reported
the following financial relationships or relationships to products or dev
ices they have with ineligible companies related to the content of this ac
tivity:
\n
\n- Matthew Frese\, MBA\, General Manager of Med Learni
ng Group\, has nothing to disclose.
\n- Christina Gallo\, SVP\, Educ
ational Development for Med Learning Group\, has nothing to disclose.
\n- Payal Patel\, PharmD\, Medical Director for Med Learning Group\, has
nothing to disclose.
\n- Lauren Welch\, MA\, VP\, Accreditation and
Outcomes for Med Learning Group\, has nothing to disclose.
\n- Aime
e Meissner\, Accreditation and Outcomes Coordinator for Med Learning Group
\, has nothing to disclose.
\n- Felecia Beachum\, Sr. Program Manage
r for Med Learning Group\, has nothing to disclose.
\n- Naomi De Bri
to\, Associate Program Manager for Med Learning Group\, has nothing to dis
close.
\n
\n
DISCLOSURE OF UNLABELED USE
\n
Med Learning Group requires that faculty participating in any CME act
ivity disclose to the audience when discussing any unlabeled or investigat
ional use of any commercial product or device not yet approved for use in
the United States.
\nDuring this lecture\, the faculty may mention th
e use of medications for both FDA-approved and non-approved indications.
p>\n
METHOD OF PARTICIPATION
\n
There are no fee
s for participating and receiving CE credit for this activity.
\n
In
order to obtain your certificate for the mentioned accreditation\, partici
pants need to successfully complete the associated pre/post activities and
evaluation.
\n
Your certificate will be provided as a downloadable f
ile.
\n
DISCLAIMER
\n
Med Learning Group mak
es every effort to develop CME activities that are science based. This act
ivity is designed for educational purposes. Participants have a responsibi
lity to use this information to enhance their professional development in
an effort to improve patient outcomes. Conclusions drawn by the participan
ts should be derived from careful consideration of all available scientifi
c information. The participant should use his/her clinical judgment\, know
ledge\, experience\, and diagnostic decision making before applying any in
formation\, whether provided here or by others\, for any professional use.
\n
For CME questions\, please contact Med Learning Group at info@medlearninggroup.c
om
\n
Contact this CME provider at Med Learning Group for privacy
and confidentiality policy statement information at https://medlearninggroup
.com/privacy-policy/
\n
AMERICANS WITH DISABILITIES ACT<
/strong>
\n
Event staff will be glad to assist you with any special
needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.
com
\n
RELEASED DATE: November 30\, 2023
\n
EXPIRATION DATE: November 30\, 2024
\n
\n
Copyright © 2023 Med Learning Group. All
rights reserved. These materials may be used for personal use only. Any r
ebroadcast\, distribution\, or reuse of this presentation or any part of i
t in any form for other than personal use without the express written perm
ission of Med Learning Group is prohibited.
\n
\n
\n
VIEW ACTIVITY
\n\n
\n
\n
END:VEVENT
END:VCALENDAR